<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">SMM</journal-id>
<journal-id journal-id-type="hwp">spsmm</journal-id>
<journal-id journal-id-type="nlm-ta">Stat Methods Med Res</journal-id>
<journal-title>Statistical Methods in Medical Research</journal-title>
<issn pub-type="ppub">0962-2802</issn>
<issn pub-type="epub">1477-0334</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0962280211432512</article-id>
<article-id pub-id-type="publisher-id">10.1177_0962280211432512</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The network meta-analytic-predictive approach to non-inferiority trials</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Schmidli</surname><given-names>Heinz</given-names></name>
<xref ref-type="aff" rid="aff1-0962280211432512">1</xref>
<xref ref-type="corresp" rid="corresp1-0962280211432512"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Wandel</surname><given-names>Simon</given-names></name>
<xref ref-type="aff" rid="aff2-0962280211432512">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Neuenschwander</surname><given-names>Beat</given-names></name>
<xref ref-type="aff" rid="aff2-0962280211432512">2</xref>
</contrib>
<aff id="aff1-0962280211432512"><label>1</label>Statistical Methodology, Development, Novartis Pharma AG, CH-4002 Basel, Switzerland</aff>
<aff id="aff2-0962280211432512"><label>2</label>Biometrics, Oncology, Novartis Pharma AG, CH-4002 Basel, Switzerland</aff>
</contrib-group>
<contrib-group content-type="issue">
<contrib contrib-type="guest-editor">
<name><surname>Julious</surname><given-names>Steven A</given-names></name>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0962280211432512">Heinz Schmidli, Novartis Pharma AG, P.O. Box, CH-4002 Basel, Switzerland. Email: <email>heinz.schmidli@novartis.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>2</issue>
<issue-title>Special Issue: Meta analysis in Clinical Research</issue-title>
<fpage>219</fpage>
<lpage>240</lpage>
<permissions>
<copyright-statement>© The Author(s) 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>In non-inferiority clinical trials, a test treatment is compared to an active-control rather than to placebo. Such designs are considered when placebo is unethical or not feasible. The critical question is whether the test treatment would have been superior to placebo, had placebo been used in the non-inferiority trial. This question can only be addressed indirectly, based on information from relevant historical trials with data on active-control and placebo. The network meta-analytic-predictive approach to non-inferiority trials is based on a network meta-analysis of the data from the historical trials and the non-inferiority trial, and the prediction of the putative test vs. placebo effect in the non-inferiority trial. The approach extends previous work by incorporating between-trial variability for all relevant parameters and focusing on the parameters in the non-inferiority trial rather than on population means. Two prominent examples with binary outcomes are used to illustrate the approach.</p>
</abstract>
<kwd-group>
<kwd>Bayesian inference</kwd>
<kwd>clinical trial</kwd>
<kwd>generalized linear model</kwd>
<kwd>meta-analysis</kwd>
<kwd>mixed treatment comparison</kwd>
<kwd>NetMAP</kwd>
<kwd>network meta-analysis</kwd>
<kwd>non-inferiority</kwd>
<kwd>random effects</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0962280211432512" sec-type="intro"><title>1 Introduction</title>
<p>A randomized clinical trial comparing a test (experimental) treatment with placebo provides direct evidence on the efficacy of the test treatment. However, when at least one effective therapy is already available, use of placebo in a randomized clinical trial may not be ethical or feasible, especially in life-threatening diseases. A reasonable option may then be a non-inferiority trial, where patients are randomized to a test treatment and an active-control treatment.<sup><xref ref-type="bibr" rid="bibr1-0962280211432512">1</xref>–<xref ref-type="bibr" rid="bibr3-0962280211432512">3</xref></sup> Although such a non-inferiority trial provides information on the similarity of efficacy between test treatment and active-control, the minimal efficacy requirement for a test treatment is still to be superior to placebo. The first important question to address when evaluating a non-inferiority trial is therefore: would the test treatment have shown superior efficacy compared to placebo, had a placebo group been included in this clinical trial?<sup><xref ref-type="bibr" rid="bibr4-0962280211432512">4</xref>–<xref ref-type="bibr" rid="bibr6-0962280211432512">6</xref></sup></p>
<p>In order to answer this question, a comparison of the test treatment to a putative placebo in the same trial is needed, based on information external to the non-inferiority trial, such as data from historical clinical trials involving the active-control and placebo. Meta-analytic methods can then be used to synthesize the available evidence,<sup><xref ref-type="bibr" rid="bibr7-0962280211432512">7</xref>,<xref ref-type="bibr" rid="bibr8-0962280211432512">8</xref></sup> and these methods are commonly used in the context of non-inferiority trials.<sup><xref ref-type="bibr" rid="bibr9-0962280211432512">9</xref>–<xref ref-type="bibr" rid="bibr11-0962280211432512">11</xref></sup></p>
<p>However, typically only historical randomized trials comparing placebo with the active-control are considered. As usually only very few such clinical trials exist, considerable uncertainty on the difference between placebo and the active-control across trials remains. To increase the reliability of this comparison, a whole network of historical clinical trials directly or indirectly linked to either placebo or the active-control can be considered in the evaluation of the non-inferiority trial.<sup><xref ref-type="bibr" rid="bibr12-0962280211432512">12</xref></sup> Network meta-analyses<sup><xref ref-type="bibr" rid="bibr13-0962280211432512">13</xref>–<xref ref-type="bibr" rid="bibr18-0962280211432512">18</xref></sup> extend the more common two-group meta-analysis to comparisons of multiple treatments. This approach is increasingly used to provide evidence on the relative efficacy of therapies.<sup><xref ref-type="bibr" rid="bibr19-0962280211432512">19</xref>–<xref ref-type="bibr" rid="bibr21-0962280211432512">21</xref></sup></p>
<p>The methodological and practical focus in network meta-analysis is typically on the population mean differences of the considered treatments. In the context of non-inferiority, interest centres on the treatment contrast in the non-inferiority trial, and there mainly on the comparison between test treatment and putative placebo.</p>
<p>We consider the case of a binary outcome within the framework of generalized linear mixed models to integrate the non-inferiority trial and the relevant historical trials within a common network. The model is then used to predict the difference between putative placebo and the test treatment in the non-inferiority trial. Between-trial variability of treatment effects will be accounted for, which is an important component of the proposed approach, as it avoids an overly confident use of the indirect evidence from the historical data.</p>
<p>The article is structured as follows. In Section 2, the network meta-analytic-predictive (NetMAP) approach to non-inferiority trials is described for the case of three treatments (test, active-control and placebo). Section 3 illustrates the proposed approach with two examples. The first example re-evaluates an analysis by Simon,<sup><xref ref-type="bibr" rid="bibr22-0962280211432512">22</xref></sup> highlighting the importance of considering the predicted active-control vs. placebo effect rather than the mean effect. The second example discusses the PRoFESS study,<sup><xref ref-type="bibr" rid="bibr23-0962280211432512">23</xref></sup> a large non-inferiority trial in recurrent stroke with a rich historical database on five treatments, whose perceived inconsistency with previous evidence<sup><xref ref-type="bibr" rid="bibr20-0962280211432512">20</xref></sup> created much debate.<sup><xref ref-type="bibr" rid="bibr24-0962280211432512">24</xref>–<xref ref-type="bibr" rid="bibr26-0962280211432512">26</xref></sup> Section 4 briefly summarizes other approaches to the analysis of non-inferiority trials, and regulatory guidelines. The article closes with a discussion.</p>
</sec>
<sec id="sec2-0962280211432512"><title>2 Methods</title>
<p>In this section, we consider a non-inferiority trial comparing a test treatment (T) with an active-control (C), where the primary endpoint is binary. We will discuss the basic NetMAP approach, which incorporates historical data in order to assess the effect of the test treatment vs. the putative placebo (P). In the following, the term placebo is used loosely, and may also refer to a standard of care treatment.</p>
<p>In the sequel, it will be assumed that data are available from the non-inferiority (NI) and K historical trials, and that three treatment groups are involved: active-control C with both historical and NI trial data, placebo P with historical data only and test treatment T with NI trial data only. <xref ref-type="table" rid="table1-0962280211432512">Table 1</xref> provides an overview of the basic NetMAP framework for a binary outcome (Sections 2.1 and 2.2) with historical trials indexed by <italic>i</italic> = 1,…, <italic>K</italic> and the non-inferiority trial indexed by the star symbol (*).
<table-wrap id="table1-0962280211432512" position="float"><label>Table 1.</label><caption><p>NetMAP model for historical trials and non-inferiority trial, with sampling model, parameter model and prior distributions</p></caption>
<graphic alternate-form-of="table1-0962280211432512" xlink:href="10.1177_0962280211432512-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Historical trials (<italic>i</italic> = 1,…, <italic>K</italic>)</th>
<th>Non-inferiority trial</th>
</tr></thead>
<tbody align="left">
<tr>
<td colspan="3"><italic>Event probabilities</italic></td>
</tr>
<tr>
<td> Active-control</td>
<td><inline-formula id="ilm1-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math1-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula></td>
<td><inline-formula id="ilm2-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math2-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula></td>
</tr>
<tr>
<td> Placebo</td>
<td><inline-formula id="ilm3-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math3-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula></td>
<td><inline-formula id="ilm4-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math4-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula></td>
</tr>
<tr>
<td> Test</td>
<td><inline-formula id="ilm5-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math5-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula></td>
<td><inline-formula id="ilm6-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math6-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula></td>
</tr>
<tr>
<td colspan="3"><italic>Sampling model</italic></td>
</tr>
<tr>
<td> Active-control</td>
<td><inline-formula id="ilm7-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math7-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> ∼ Bin(<inline-formula id="ilm8-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math8-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilm9-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math9-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>)</td>
<td><inline-formula id="ilm10-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math10-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> ∼ Bin(<inline-formula id="ilm11-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math11-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilm12-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math12-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>)</td>
</tr>
<tr>
<td> Placebo  Test</td>
<td><inline-formula id="ilm13-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math13-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> ∼ Bin(<inline-formula id="ilm14-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math14-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilm15-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math15-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>)</td>
<td> <inline-formula id="ilm16-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math16-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> ∼ Bin(<inline-formula id="ilm17-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math17-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilm18-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math18-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>)</td>
</tr>
<tr>
<td colspan="3"><italic>Parameter model and transformations</italic></td>
</tr>
<tr>
<td colspan="3">Transformations: <italic>θ</italic> = log-odds(<italic>π</italic>), <italic>δ</italic> = log-odds-ratios</td>
</tr>
<tr>
<td> Active-control</td>
<td align="center" colspan="2"><inline-formula id="ilm19-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math19-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>,…, <inline-formula id="ilm20-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math20-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilm21-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math21-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> ∼ <italic>N</italic>(<italic>µ<sub>θ</sub></italic>, <inline-formula id="ilm22-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math22-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>)</td>
</tr>
<tr>
<td> Placebo vs. active-control</td>
<td align="center" colspan="2"><inline-formula id="ilm23-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math23-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>,…, <inline-formula id="ilm24-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math24-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilm25-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math25-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> ∼ <italic>N</italic>(<italic>µ<sub>P</sub><sub>C</sub></italic>, <inline-formula id="ilm26-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math26-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>)</td>
</tr>
<tr>
<td> Test vs. active-control</td>
<td align="center" colspan="2"><inline-formula id="ilm27-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math27-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TC</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>,…, <inline-formula id="ilm28-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math28-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TC</mml:mi></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilm29-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math29-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> ∼ <italic>N</italic>(<italic>µ<sub>TC</sub></italic>, <inline-formula id="ilm30-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math30-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>)</td>
</tr>
<tr>
<td colspan="3"><italic>Prior distributions</italic></td>
</tr>
<tr>
<td> Random effect means</td>
<td align="center" colspan="2"><italic>µ<sub>θ</sub></italic>, <italic>µ<sub>P</sub><sub>C</sub></italic>, <italic>µ<sub>TC</sub></italic> ∼ <italic>N</italic>(0,100<sup>2</sup>)</td>
</tr>
<tr>
<td> Random-effects standard deviations</td>
<td align="center" colspan="2"><italic>τ<sub>θ</sub></italic> ∼ Half-Normal(<italic>σ</italic><sup>2 </sup>= 0.5<sup>2</sup>)</td>
</tr>
<tr>
<td align="center" colspan="2"><italic>τ<sub>δ</sub></italic> ∼ Half-Normal(<italic>σ</italic><sup>2 </sup>= 0.25<sup>2</sup>)</td>
</tr>
</tbody>
</table>
</table-wrap></p>
<sec id="sec3-0962280211432512"><title>2.1 Sampling model</title>
<p>In the non-inferiority trial, the number of events <inline-formula id="ilm31-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math31-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilm32-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math32-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> in the test and active-control group follow binomial distributions,
<disp-formula id="disp-formula1-0962280211432512"><label>(1a)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math1-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo>~</mml:mo><mml:mtext>Bin</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo>~</mml:mo><mml:mtext>Bin</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo/></mml:mrow></mml:mrow></mml:math><graphic alternate-form-of="disp-formula1-0962280211432512" xlink:href="10.1177_0962280211432512-eq1.tif"/></disp-formula>
with corresponding true event probabilities <inline-formula id="ilm33-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math33-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilm34-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math34-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> and number of patients <inline-formula id="ilm35-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math35-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilm36-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math36-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> for the test and active-control group, respectively.</p>
<p>In principle, for three treatments, there are three comparisons of interest. In the non-inferiority setting, the main question is whether the test treatment would have been superior to placebo, had the latter been part of the NI trial. Thus, interest is in comparing <inline-formula id="ilm37-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math37-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> with <inline-formula id="ilm38-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math38-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>, where for the latter no direct evidence is available due to the fact that placebo is not part of the NI trial.</p>
<p>The historical trials provide data for placebo and active-control,
<disp-formula id="disp-formula2-0962280211432512"><label>(1b)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math2-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:mo>~</mml:mo><mml:mtext>Bin</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:mo>~</mml:mo><mml:mtext>Bin</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo/></mml:mrow><mml:mo>…</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:mi>K</mml:mi><mml:mrow><mml:mo/></mml:mrow></mml:mrow></mml:math><graphic alternate-form-of="disp-formula2-0962280211432512" xlink:href="10.1177_0962280211432512-eq2.tif"/></disp-formula>
where <inline-formula id="ilm39-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math39-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilm40-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math40-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilm41-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math41-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilm42-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math42-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilm43-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math43-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilm44-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math44-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> are the number of events, number of patients and true event probabilities in historical trial <italic>i</italic>. It should be noted that it is not required that data for both treatment arms (P and C) are available for all the historical trials, although this will often be the case.</p>
</sec>
<sec id="sec4-0962280211432512"><title>2.2 Parameter model</title>
<p>For the non-inferiority setting with <italic>K</italic> historical trials and three treatments, the network has (<italic>K</italic> + 1) × 3 parameters, the true event probabilities for C, P and T in all the trials. To address the main question, the comparison of the test treatment with the putative placebo in the NI trial, assumptions regarding the relationship among the parameters are unavoidable. That is, a parameter model for the network of trials, which links the parameters of the non-inferiority trial with those of the historical trials, is needed.</p>
<p>The parameter model of this section will be based on transformed parameters. First, since the active-control is a part of both the non-inferiority and the historical trials, the active-control group will be used as the reference group, with its parameters transformed to the log-odds scale, i.e.
<disp-formula id="disp-formula3-0962280211432512"><label>(2a)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math3-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mtext>logit</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:mtext>and</mml:mtext><mml:msubsup><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mtext>logit</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo/></mml:mrow><mml:mo>…</mml:mo><mml:mi>K</mml:mi><mml:mrow><mml:mo/></mml:mrow></mml:mrow></mml:math><graphic alternate-form-of="disp-formula3-0962280211432512" xlink:href="10.1177_0962280211432512-eq3.tif"/></disp-formula>
where logit(<italic>π</italic>) = log{<italic>π</italic>/(1 − <italic>π</italic>)}. This transformation is convenient and will be useful when expressing a probabilistic relationship among the parameters. Second, treatment effects will be expressed on the log-odds-ratio scale, i.e. for the placebo vs. active-control log-odds-ratios
<disp-formula id="disp-formula4-0962280211432512"><label>(2b)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math4-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mtext>logit</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>-</mml:mo><mml:mtext>logit</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:mtext>and</mml:mtext><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mtext>logit</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>-</mml:mo><mml:mtext>logit</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo/></mml:mrow><mml:mo>…</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:mi>K</mml:mi><mml:mrow><mml:mo/></mml:mrow></mml:mrow></mml:math><graphic alternate-form-of="disp-formula4-0962280211432512" xlink:href="10.1177_0962280211432512-eq4.tif"/></disp-formula>
and for the test vs. active-control log-odds-ratios
<disp-formula id="disp-formula6-0962280211432512"><label>(2c)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math6-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mtext>logit</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>-</mml:mo><mml:mtext>logit</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:mtext>and</mml:mtext><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TC</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mtext>logit</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>-</mml:mo><mml:mtext>logit</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo/></mml:mrow><mml:mo>…</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:mi>K</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic alternate-form-of="disp-formula6-0962280211432512" xlink:href="10.1177_0962280211432512-eq6.tif"/></disp-formula>
 </p>
<p>As to the relationship across the reference parameters or the effect parameters, different assumptions are possible, ranging from assuming that the parameters are the same over all trials (equal to a common parameter) to that the <italic>K</italic> + 1 parameters differ and are completely unrelated.</p>
<p>For the reference (active-control) group parameters (log-odds), the first assumption is unrealistic due to heterogeneity of event rates across trials. This is why in standard meta-analysis, the parameters of the control group are treated as nuisance parameters, in the form of the second assumption.</p>
<p>For the treatment effects (log-odds-ratios), the most often used method in meta-analysis is the common-effect model, which is the first assumption. However, this model has been criticized as being unrealistic due to the fact that heterogeneity across trials is always present (and small at best),<sup><xref ref-type="bibr" rid="bibr8-0962280211432512">8</xref></sup> although it is commonly acknowledged that on a relative scale (e.g. log-odds-ratio), this heterogeneity is typically considerably smaller than for the parameters of one group (log-odds of event rates). In the NI setting, assuming a common log-odds-ratio for P vs. C for the historical and the NI trial is the ‘constancy’ assumption, which we think is rightly seen as an assumption that is fairly strong and hard to justify.</p>
<p>In the light of these considerations, and the fact that the two assumptions lead to very similar results compared to using a random-effects model with small or large between-trial heterogeneity, respectively, we will use random-effects as the default for all transformed parameters. For the log-odds of the active-control group, the assumption is
<disp-formula id="disp-formula7-0962280211432512"><label>(3a)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math7-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:mo/></mml:mrow><mml:mo>…</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:msubsup><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo/></mml:mrow></mml:mrow></mml:math><graphic alternate-form-of="disp-formula7-0962280211432512" xlink:href="10.1177_0962280211432512-eq7.tif"/></disp-formula>
 and for the treatment effects (log-odds-ratios for P and T vs. C)
<disp-formula id="disp-formula8-0962280211432512"><label>(3b)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math8-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:mo/></mml:mrow><mml:mo>…</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:msubsup><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><graphic alternate-form-of="disp-formula8-0962280211432512" xlink:href="10.1177_0962280211432512-eq8.tif"/></disp-formula>
 
<disp-formula id="disp-formula9-0962280211432512"><label>(3c)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math9-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TC</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:mo/></mml:mrow><mml:mo>…</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TC</mml:mi></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:msubsup><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi>TC</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><graphic alternate-form-of="disp-formula9-0962280211432512" xlink:href="10.1177_0962280211432512-eq9.tif"/></disp-formula>
 where <italic>µ<sub>θ</sub></italic>, <italic>µ<sub>P</sub><sub>C</sub></italic> and <italic>µ<sub>T</sub><sub>C</sub></italic> are the means of the random-effects distributions, and <italic>τ<sub>θ</sub></italic> and <italic>τ<sub>δ</sub></italic> are the corresponding between-trial standard deviations. In this formulation, the between-trial standard deviations for the log-odds-ratios (against active-control) are assumed to be equal for placebo and test treatment, an assumption that could be relaxed if necessary,<sup><xref ref-type="bibr" rid="bibr13-0962280211432512">13</xref>,<xref ref-type="bibr" rid="bibr27-0962280211432512">27</xref></sup> using either unrelated or exchangeable standard deviations. Also, a bivariate normal random-effects distribution is typically used in (3b) and (3c), with correlation equal to 0.5 (the model that will be used in the sequel), or unknown; for details and extensions of this standard model used in evidence synthesis, see, for example, Lu and Ades.<sup><xref ref-type="bibr" rid="bibr16-0962280211432512">16</xref></sup></p>
<p>The above model is very similar to the corresponding model in Lu and Ades.<sup><xref ref-type="bibr" rid="bibr16-0962280211432512">16</xref></sup> However, we have parametrized the model differently by choosing the active-control group as the reference group, rather than the mean of the log-odds over all treatment groups. The former choice seems quite natural in the context of non-inferiority trials, since the active-control group is a part of both the non-inferiority and the historical trials, i.e. data from the active-control group maximize the information about between-trial heterogeneity. We note that the specification (3c) for the T vs. C log-odds-ratios is only needed when the test treatment has also been studied in the historical trials.</p>
<p>In (3a), event probabilities in the active-control group are modelled by random-effects, an assumption considered by several authors.<sup><xref ref-type="bibr" rid="bibr16-0962280211432512">16</xref>,<xref ref-type="bibr" rid="bibr28-0962280211432512">28</xref>–<xref ref-type="bibr" rid="bibr32-0962280211432512">32</xref></sup> Treating these parameters as completely unrelated (fixed) parameters is an alternative:
<disp-formula id="disp-formula10-0962280211432512"><label>(3a′)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math10-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:mo/></mml:mrow><mml:mo>…</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:msubsup><mml:mtext>unrelated</mml:mtext><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic alternate-form-of="disp-formula10-0962280211432512" xlink:href="10.1177_0962280211432512-eq10.tif"/></disp-formula>
 </p>
<p>However, in the situation where the data suggest considerable between-trial heterogeneity for the active-control group log-odds (standard deviations <italic>τ<sub>θ</sub></italic> &gt; 0.5, say), differences in the results from the random vs. fixed-effects assumption are typically small. On the other hand, if between-trial heterogeneity for the active-control log-odds is small, additional information is gained for the analysis of the NI trial using the random-effects assumption. The random-effect model for the active-control group also allows to predict the active-control and placebo event probabilities (<inline-formula id="ilm45-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math45-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilm46-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math46-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>) in the non-inferiority trial, which is especially useful in the planning stage. Inference on these parameters is not possible when assuming unrelated event probabilities in the control group as in (3a′).</p>
</sec>
<sec id="sec5-0962280211432512"><title>2.3 Inferential approach</title>
<p>The network meta-analysis models belong to the class of generalized linear mixed models, and hence can be fitted by standard software.</p>
<p>Likelihood-based methods can be used to estimate model parameters and derive confidence intervals.<sup><xref ref-type="bibr" rid="bibr7-0962280211432512">7</xref>,<xref ref-type="bibr" rid="bibr33-0962280211432512">33</xref></sup> In the context of non-inferiority trials, the prediction of the difference between test treatment and placebo (<inline-formula id="ilm47-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math47-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TP</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>) is of main interest. Confidence intervals for predictions in random-effect models can be based on normal or <italic>t</italic>-approximations.<sup><xref ref-type="bibr" rid="bibr8-0962280211432512">8</xref></sup></p>
<p>In the Bayesian framework, inference for the network meta-analytic models is technically relatively straightforward. However, care is needed for the prior distributions of the model parameters. Priors for the random-effect means are unproblematic, and vague normal priors are often used, such as:
<disp-formula id="disp-formula11-0962280211432512"><label>(4a)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math11-0962280211432512"><mml:mrow><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mrow><mml:mo/></mml:mrow><mml:msup><mml:mrow><mml:mn>100</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mrow><mml:mo/></mml:mrow><mml:msup><mml:mrow><mml:mn>100</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi>TC</mml:mi></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mrow><mml:mo/></mml:mrow><mml:msup><mml:mrow><mml:mn>100</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic alternate-form-of="disp-formula11-0962280211432512" xlink:href="10.1177_0962280211432512-eq11.tif"/></disp-formula>
 </p>
<p>More critical are the priors for the between-trial standard deviations <italic>τ<sub>θ</sub></italic> and <italic>τ<sub>δ</sub></italic>.<sup><xref ref-type="bibr" rid="bibr34-0962280211432512">34</xref>,<xref ref-type="bibr" rid="bibr35-0962280211432512">35</xref></sup> The prior for the standard deviation of the between-trial log-odds parameters will be
<disp-formula id="disp-formula12-0962280211432512"><label>(4b)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math12-0962280211432512"><mml:mrow><mml:msub><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mtext>Half - Normal</mml:mtext><mml:mo> </mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:msup><mml:mrow><mml:mo>.</mml:mo><mml:mn>5</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><graphic alternate-form-of="disp-formula12-0962280211432512" xlink:href="10.1177_0962280211432512-eq12.tif"/></disp-formula>
where the half-normal distribution Half-Normal(<italic>σ</italic><sup>2</sup>) is defined as the normal distribution <italic>N</italic>(0,<italic>σ</italic><sup>2</sup>), restricted to positive values. The mean and median values for <italic>τ<sub>θ</sub></italic> are 0.34 and 0.40, respectively, and the 95% prior probability interval is (0.016,1.12). Since a standard deviation of <italic>τ<sub>θ</sub></italic> = 0.5 on the log-odds scale represents already fairly substantial between-trial heterogeneity, we think that the chosen prior covers a wide range of plausible scenarios for between-trial heterogeneity. For example, if the population median of active-control proportions is 0.5, then the above prior for the between-trial standard deviation <italic>τ<sub>θ</sub></italic> implies that the true active-control proportion in a new trial is between 0.25 and 0.75 with 95% probability. In some indications, this prior may be too narrow or too wide, and should then be adapted.</p>
<p>Due to the fact that log-odds-ratios are typically much less heterogeneous across trials, the prior for the between-trial standard deviation will be chosen as
<disp-formula id="disp-formula13-0962280211432512"><label>(4c)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math13-0962280211432512"><mml:mrow><mml:msub><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mi>δ</mml:mi></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mtext>Half - Normal</mml:mtext><mml:mo> </mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:msup><mml:mrow><mml:mo>.</mml:mo><mml:mn>25</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic alternate-form-of="disp-formula13-0962280211432512" xlink:href="10.1177_0962280211432512-eq13.tif"/></disp-formula>
 </p>
<p>The mean and median for <italic>τ<sub>δ</sub></italic> are 0.17 and 0.20, respectively, and the 95% prior probability interval is (0.008,0.56). For example, when the population median of the odds-ratio comparing placebo to active-control is 1.5, then the true odds-ratio in a new trial is between 0.87 and 2.59 with 95% probability. Again, this prior can be changed if it is considered too wide or too narrow in a particular indication.</p>
<p>In summary, we think that the two priors cover a range of plausible values (from small to large heterogeneity), which would seem reasonable for a wide range of diseases and treatments. The priors can be adapted if more information about heterogeneity is available, for example based on a review of several meta-analyses.<sup><xref ref-type="bibr" rid="bibr13-0962280211432512">13</xref>,<xref ref-type="bibr" rid="bibr36-0962280211432512">36</xref></sup> In network meta-analyses, the number of studies is typically small, and hence care must be taken to avoid unintended prior information. Sensitivity analyses to assess the impact of different believable priors may also be useful.</p>
<p>Here, we have modelled the event probabilities in the active-control group by random-effects. Alternatively, when these are rather considered as unrelated parameters, then vague prior distributions should be used for the active-control parameters:
<disp-formula id="disp-formula14-0962280211432512"><label>(4d)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math14-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:mo/></mml:mrow><mml:mo>…</mml:mo><mml:mrow><mml:mo/></mml:mrow><mml:msubsup><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:msubsup><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mrow><mml:mo/></mml:mrow><mml:msup><mml:mrow><mml:mn>100</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic alternate-form-of="disp-formula14-0962280211432512" xlink:href="10.1177_0962280211432512-eq14.tif"/></disp-formula>
 </p>
<p>Bayesian inference is based on the joint posterior distribution of the parameters given the data. Gibbs sampling<sup><xref ref-type="bibr" rid="bibr37-0962280211432512">37</xref></sup> as implemented in WinBUGS<sup><xref ref-type="bibr" rid="bibr38-0962280211432512">38</xref></sup> can be used to generate a sample from the joint posterior distribution. The WinBUGS code for the basic NetMAP model with three treatments is provided in the appendix.</p>
</sec>
<sec id="sec6-0962280211432512"><title>2.4 Outcomes of interest</title>
<p>The NetMAP model comprises the main parameters (event rates) for the three treatment groups, and the effect parameters (log-odds-ratios) comparing placebo and test treatment to active-control. In addition, between-trial variability is captured by random-effects for the log-odds of the active-control group and the P vs. C log-odds-ratios.</p>
<p>In principle, all model parameters could be of interest. In the examples of Section 3, we will mainly show results for the following ones: The comparisons (direct and indirect) for all treatments in the non-inferiority trial, where the test vs. placebo effect, i.e. the log-odds-ratio <inline-formula id="ilm48-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math48-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TP</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> = <inline-formula id="ilm49-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math49-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> − <inline-formula id="ilm50-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math50-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>, is of particular interest; The amount of between-trial heterogeneity, expressed by the between-trial standard deviations <italic>τ<sub>θ</sub></italic> and <italic>τ<sub>δ</sub></italic>.</p>
</sec>
</sec>
<sec id="sec7-0962280211432512"><title>3 Examples</title>
<p>In this section, we use two prominent non-inferiority trials to illustrate the NetMAP approach. The examples represent two typical data structures. The historical data in the first example are minimal in the sense that it only comprises data on active-control and placebo, whereas in the second example, the historical database is much richer, including the test treatment used in the non-inferiority trial as well as additional treatments.</p>
<sec id="sec8-0962280211432512"><title>3.1 ESSENCE non-inferiority trial</title>
<sec id="sec9-0962280211432512"><title>3.1.1 Background and data</title>
<p>The ESSENCE randomized non-inferiority trial<sup><xref ref-type="bibr" rid="bibr39-0962280211432512">39</xref></sup> compared the test treatment (T: aspirin + enoxaparin) with the active-control (C: aspirin + heparin) in more than 3000 patients with unstable angina or non-Q-wave myocardial infarction. The binary efficacy variable considered here is the composite endpoint of death or myocardial infarction (MI) at day 30, and treatments are compared based on odds-ratios. As patients in both treatment arms received aspirin, this is the putative placebo (P: aspirin). The main question is whether the test treatment would have been superior to placebo, had the latter been included in the ESSENCE trial. Historical information is needed to answer this question. Six randomized historical trials comparing active-control and placebo had been conducted prior to the ESSENCE trial.<sup><xref ref-type="bibr" rid="bibr40-0962280211432512">40</xref></sup> The data of the six historical trials and of the non-inferiority trial are given in <xref ref-type="table" rid="table2-0962280211432512">Table 2</xref>.
<table-wrap id="table2-0962280211432512" position="float"><label>Table 2.</label><caption><p>Data (events/patients) from the ESSENCE non-inferiority trial and six historical trials, for active-control (C: aspirin + heparin), placebo (P: aspirin) and test (T: aspirin + enoxaparin) treatment. The ORs against the active-control are also shown</p></caption>
<graphic alternate-form-of="table2-0962280211432512" xlink:href="10.1177_0962280211432512-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Test</th>
<th>Active-control</th>
<th>Placebo</th>
<th>OR (95% CI)<sup><xref ref-type="table-fn" rid="table-fn1-0962280211432512">a</xref></sup> vs. Active-control</th>
</tr></thead>
<tbody align="left">
<tr>
<td colspan="4">ESSENCE non-inferiority trial</td>
</tr>
<tr>
<td>99/1607 (6.2%)</td>
<td>121/1564 (7.7%)</td>
<td>0.78 (0.60, 1.03)</td>
</tr>
<tr>
<td colspan="4">Historical trials</td>
</tr>
<tr>
<td>2/122 (1.6%)</td>
<td>4/121 (3.3%)</td>
<td>1.85 (0.39, 8.84)</td>
</tr>
<tr>
<td>3/210 (1.4%)</td>
<td>7/189 (3.7%)</td>
<td>2.44 (0.67, 8.80)</td>
</tr>
<tr>
<td>0/37 (0%)</td>
<td>1/32 (3.1%)</td>
<td>3.57 (0.14, 90.8)</td>
</tr>
<tr>
<td>4/105 (3.8%)</td>
<td>9/109 (8.3%)</td>
<td>2.13 (0.67, 6.77)</td>
</tr>
<tr>
<td>42/154 (27.3%)</td>
<td>40/131 (30.5%)</td>
<td>1.17 (0.70, 1.95)</td>
</tr>
<tr>
<td>4/70 (5.7%)</td>
<td>7/73 (9.6%)</td>
<td>1.67 (0.49, 5.63)</td>
</tr>
<tr>
<td>Total</td>
<td>55/698 (7.9%)</td>
<td>68/655 (10.4%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0962280211432512"><p>Note: OR = odds-ratios.</p></fn>
<fn id="table-fn2-0962280211432512"><label>a</label><p>Calculated after adding 0.5 to each cell of the 2 × 2 table.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>In the following, we first evaluate the historical data only to assess whether the chosen active-control is appropriate. Such analyses are useful at the design stage. Then, we analyse the data from both the historical trials and the non-inferiority trial using the NetMAP approach of Section 2. This allows to evaluate whether the test treatment would have been superior to placebo, had placebo been included in the non-inferiority trial. Finally, the results obtained here are compared with a previous analysis by Simon.<sup><xref ref-type="bibr" rid="bibr22-0962280211432512">22</xref></sup></p>
</sec>
<sec id="sec10-0962280211432512"><title>3.1.2 Analysis using historical data only</title>
<p>The choice of an appropriate active-control is important in the design stage of a non-inferiority trial. The active-control should reliably outperform placebo in a new trial. This can be addressed by a meta-analysis of the historical trials comparing active-control and placebo, focusing on the predicted odds-ratio between placebo and active-control in a new trial (i.e. the non-inferiority trial). As seen in <xref ref-type="table" rid="table3-0962280211432512">Table 3</xref>, panel A, the active-control tends to be better than placebo, with a predicted odds-ratio (P vs. C) of exp(<inline-formula id="ilm51-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math51-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>) = 1.53. The probability that the odds-ratio will be greater than 1 in the non-inferiority trial is 93.2%. Although this gives some assurance that the active-control would show better efficacy than placebo in a new trial, the evidence is not particularly strong in a regulatory context, where probabilities larger than 97.5% are typically considered necessary. It should be noted that based on the random-effects mean <italic>µ<sub>P</sub><sub>C</sub></italic>, the probability that active-control is better than placebo is 96.9%, which reflects the increased precision for the mean parameter compared to the prediction.
<table-wrap id="table3-0962280211432512" position="float"><label>Table 3.</label><caption><p>Results (posterior medians and 95%-intervals) from the NetMAP analysis using six historical trials, with (third column) and without (second column) the ESSENCE non-inferiority trial, for active-control (C: aspirin +  heparin), placebo (P: aspirin) and test (T: aspirin + enoxaparin) treatment</p></caption>
<graphic alternate-form-of="table3-0962280211432512" xlink:href="10.1177_0962280211432512-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Parameter</th>
<th colspan="2">Posterior distribution: median (95%-interval)</th>
</tr>
<tr><th>Historical</th>
<th>Historical and non-inferiority</th>
</tr></thead>
<tbody align="left">
<tr>
<td colspan="3"><italic>Panel A: Random effect model for active-control event probabilities</italic></td>
</tr>
<tr>
<td colspan="3"><italic>Between-trial standard deviations for log-odds-ratios (vs. C), and log-odds (C)</italic></td>
</tr>
<tr>
<td> <italic>τ<sub>δ</sub></italic></td>
<td>0.14 (0.01,0.46)</td>
<td>0.14 (0.00,0.46)</td>
</tr>
<tr>
<td> <italic>τ<sub>θ</sub></italic></td>
<td>0.93 (0.60,1.46)</td>
<td>0.90 (0.58,1.40)</td>
</tr>
<tr>
<td colspan="3"><italic>Odds-ratios and probability of superiority in ESSENCE NI trial</italic></td>
</tr>
<tr>
<td> exp(<inline-formula id="ilm52-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math52-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PT</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>)</td>
<td>1.92 (0.99, 3.85)</td>
</tr>
<tr>
<td> Pr(T better than P)</td>
<td>97.4%</td>
</tr>
<tr>
<td> exp(<inline-formula id="ilm53-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math53-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>CT</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>)</td>
<td>1.27 (0.97, 1.68)</td>
</tr>
<tr>
<td> Pr(T better than C)</td>
<td>95.7%</td>
</tr>
<tr>
<td> exp(<inline-formula id="ilm54-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math54-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>)</td>
<td>1.53 (0.84, 2.94)</td>
<td>1.51 (0.83, 2.88)</td>
</tr>
<tr>
<td> Pr(C better than P)</td>
<td>93.2%</td>
<td>92.6%</td>
</tr>
<tr>
<td colspan="3"><italic>Odds-ratios and probability of superiority for mean parameter</italic></td>
</tr>
<tr>
<td> exp(<italic>µ<sub>PC</sub></italic>)</td>
<td>1.53 (0.98, 2.48)</td>
<td>1.51 (0.97, 2.42)</td>
</tr>
<tr>
<td> Pr(C better than P)</td>
<td>96.9%</td>
<td>96.7%</td>
</tr>
<tr>
<td colspan="3"><italic>Panel B: Unrelated active-control event probabilities</italic></td>
</tr>
<tr>
<td colspan="3"><italic>Between-trial standard deviations for log-odds-ratios (vs. C)</italic></td>
</tr>
<tr>
<td> <italic>τ<sub>δ</sub></italic></td>
<td>0.16 (0.01,0.51)</td>
<td>0.16 (0.01,0.51)</td>
</tr>
<tr>
<td colspan="3"><italic>Odds-ratios and probability of superiority in ESSENCE NI trial</italic></td>
</tr>
<tr>
<td> exp(<inline-formula id="ilm55-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math55-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PT</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>)</td>
<td>2.03 (1.04, 4.54)</td>
</tr>
<tr>
<td> Pr(T better than P)</td>
<td>98.0%</td>
</tr>
<tr>
<td> exp(<inline-formula id="ilm56-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math56-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>CT</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>)</td>
<td>1.28 (0.97, 1.69)</td>
</tr>
<tr>
<td> Pr(T better than C)</td>
<td>96.0%</td>
</tr>
<tr>
<td> exp(<inline-formula id="ilm57-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math57-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>)</td>
<td>1.58 (0.86, 3.42)</td>
<td>1.58 (0.86, 3.42)</td>
</tr>
<tr>
<td> Pr(C better than P)</td>
<td>94.0%</td>
<td>94.0%</td>
</tr>
<tr>
<td colspan="3"><italic>Odds-ratios and probability of superiority for mean parameter</italic></td>
</tr>
<tr>
<td> exp(<italic>µ<sub>PC</sub></italic>)</td>
<td>1.58 (0.99, 2.71)</td>
<td>1.58 (0.99, 2.71)</td>
</tr>
<tr>
<td> Pr(C better than P)</td>
<td>97.6%</td>
<td>97.6%</td>
</tr>
</tbody>
</table>
</table-wrap></p>
<p>The analysis also reveals that between-trial heterogeneity is large for the log-odds in the active-control group, with an estimate of 0.93 for <italic>τ<sub>θ</sub></italic> (a considerable posterior update compared to the prior; see Section 2.3), and a lower bound of 0.60, confirming substantial heterogeneity across trials. For the log-odds-ratios (P vs. C), heterogeneity is relatively moderate (posterior median <italic>τ<sub>δ</sub></italic> of 0.14) and not much different when compared to the prior.</p>
</sec>
<sec id="sec11-0962280211432512"><title>3.1.3 NetMAP non-inferiority analysis</title>
<p>In the non-inferiority trial, the estimated odds-ratio for C vs. T was 1.27, indicating a potential benefit for the test treatment compared to active-control. Given that the historical data provided some (although not strong) evidence for active-control being better than placebo, one would therefore expect to conclude the test treatment to be better than placebo, had the latter been included in the non-inferiority trial. The results of the NetMAP analysis (<xref ref-type="table" rid="table3-0962280211432512">Table 3</xref>, panel A) show that the evidence for this conclusion is not fully convincing, at least not when considering a probability level comparable to the standard frequentist 2.5% (one-sided) significance level: the posterior probability that the test treatment would have been superior to placebo is 97.4%. A graphical summary of the results is displayed in <xref ref-type="fig" rid="fig1-0962280211432512">Figure 1</xref>.
<fig id="fig1-0962280211432512" position="float"><label>Figure 1.</label><caption><p>NetMAP results for odds-ratios (median and 95%-intervals) based on the six historical trials only, and with both the ESSENCE non-inferiority trial and the historical trials.</p></caption><graphic xlink:href="10.1177_0962280211432512-fig1.tif"/></fig></p>
</sec>
<sec id="sec12-0962280211432512"><title>3.1.4 Remarks</title>
<p>
<list id="list2-0962280211432512" list-type="order">
<list-item><p>The ESSENCE non-inferiority trial was previously analysed in Simon,<sup><xref ref-type="bibr" rid="bibr22-0962280211432512">22</xref></sup> integrating the results of the six historical trials,<sup><xref ref-type="bibr" rid="bibr40-0962280211432512">40</xref></sup> and is also discussed in Fisher et al.<sup><xref ref-type="bibr" rid="bibr41-0962280211432512">41</xref></sup> and Durrleman and Chaikin.<sup><xref ref-type="bibr" rid="bibr42-0962280211432512">42</xref></sup> Simon calculated the posterior probability that the test treatment is superior to placebo and obtained a value of 99.4%, which is considerably higher than the value of 97.4% obtained here. The main reason for this discrepancy is that in Simon’s analysis, the posterior distribution for the mean parameters is used, while we use the posterior distribution for the parameters of the NI trial, which is wider (<xref ref-type="fig" rid="fig1-0962280211432512">Figure 1</xref>). The distinction is crucial, since the main objective is to demonstrate (indirectly) for the NI trial that the test treatment would have been superior to placebo, had placebo been included in the trial. Therefore, the parameter of interest is <inline-formula id="ilm58-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math58-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TP</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> = <inline-formula id="ilm59-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math59-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> − <inline-formula id="ilm60-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math60-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> rather than <inline-formula id="ilm61-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math61-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> − <italic>µ<sub>P</sub><sub>C</sub></italic>. Under the ‘constancy’ assumption, i.e. when between-trial heterogeneity for the log-odds-ratios (P vs. C) is assumed to be zero (<italic>τ<sub>δ</sub></italic> = 0), then the two quantities are identical. In the random-effects meta-analysis of the six historical trials,<sup><xref ref-type="bibr" rid="bibr40-0962280211432512">40</xref></sup> a test for heterogeneity was used, which was not significant. As this test has notoriously low power to detect between-trial variability if the number of trials is small, considerable uncertainty for <italic>τ<sub>δ</sub></italic> remains (<xref ref-type="table" rid="table3-0962280211432512">Table 3</xref>, panel A). The NetMAP approach allows for this uncertainty, whereas it is ignored under the ‘constancy assumption’.</p></list-item>
<list-item><p>In the NetMAP analysis, random-effects were used for the log-odds of the event probabilities in the active-control group. In this example, the assumption does not seem plausible, as one of the historical trials has a much higher event proportion than the other trials; see also Fleming.<sup><xref ref-type="bibr" rid="bibr43-0962280211432512">43</xref></sup> As an alternative, one could assume that the active-control log-odds are unrelated across trials. For this model, comparable results as from the random-effects assumption on the log-odds for the active-control group are obtained (<xref ref-type="table" rid="table3-0962280211432512">Table 3</xref>, panel B). This highlights that a random-effects assumption typically leads to similar results compared to the assumption of unrelated effects when substantial between-trial variability can be concluded from the data, as was seen in this example.</p></list-item>
<list-item><p>An often heard concern when using historical data is that too much weight is put on the historical evidence for the active-control vs. placebo effect in the non-inferiority trial. This is certainly a valid concern when basing conclusions on the ‘constancy assumption’, which ignores or denies between-trial heterogeneity. In the example, under the ‘constancy assumption’ (<italic>τ<sub>δ</sub></italic> = 0), the imputed log-odds-ratio (P vs. C) would be based on the full (non-discounted) historical information, which is worth <italic>n<sub>P</sub></italic> = 655 and <italic>n<sub>C</sub></italic> = 698 patients (<xref ref-type="table" rid="table2-0962280211432512">Table 2</xref>). The following approximation shows that allowing for between-trial heterogeneity discounts historical information considerably. Assuming the same number of patients <italic>n</italic>* for the placebo and active-control in the NI trial, the approximate standard error (s) for the estimated log-odds-ratio is</p></list-item>
</list>
<disp-formula id="disp-formula15-0962280211432512"><label>(5)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math15-0962280211432512"><mml:mrow><mml:msup><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo><mml:mrow><mml:mo/></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:math><graphic alternate-form-of="disp-formula15-0962280211432512" xlink:href="10.1177_0962280211432512-eq15.tif"/></disp-formula>
 where <inline-formula id="ilm62-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math62-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilm63-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math63-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> are the estimated event probabilities for the two treatments. In the example (Section 3.1.2), the analysis provides corresponding posterior estimates of 0.096 and 0.066, and a posterior standard deviation of the predicted log-odds-ratio of <italic>s</italic> = 0.311. From <xref ref-type="disp-formula" rid="disp-formula14-0962280211432512">Equation (5)</xref>, this corresponds to an approximate number of patients per arm of <italic>n</italic>* = 286, which is considerably lower than <italic>n<sub>P</sub></italic> = 655 and <italic>n<sub>C</sub></italic> = 698 under the ‘constancy assumption’. It is also worthwhile to note that the discounting arising from the between-trial heterogeneity is quite substantial, even though between-trial heterogeneity is moderate (see inference for <italic>τ<sub>δ</sub></italic> in <xref ref-type="table" rid="table3-0962280211432512">Table 3</xref>).</p>
</sec>
</sec>
<sec id="sec13-0962280211432512"><title>3.2 PRoFESS non-inferiority trial</title>
<sec id="sec14-0962280211432512"><title>3.2.1 Background and data</title>
<p>Survivors of an ischaemic stroke are often treated with antiplatelet agents to prevent serious vascular events such as stroke, MI or death from vascular causes. The PRoFESS non-inferiority trial<sup><xref ref-type="bibr" rid="bibr23-0962280211432512">23</xref></sup> compared two antiplatelet regimens in about 20 000 patients: the active-control (C: thienopyridine) and the test treatment (T: aspirin + dipyridamole). The binary efficacy variable considered here is the composite endpoint of stroke, MI or vascular death, and treatments are compared based on odds-ratios. In this case, the test treatment is a combination of aspirin and dipyridamole, and the relevant putative placebo treatment (P) is aspirin. Hence, the main question is whether the test treatment would have been more efficacious than aspirin, had aspirin been included in the PRoFESS trial.</p>
<p>To answer this question, historical information is used. A large number of historical randomized trials with antiplatelet regimens is available with the following treatments: active-control (C: thienopyridine), placebo (P: aspirin), test (T: aspirin + dipyridamole), another active treatment (A: aspirin + thienopyridine) and background therapy (B).</p>
<p>A recent network meta-analysis was described in Thijs et al.,<sup><xref ref-type="bibr" rid="bibr20-0962280211432512">20</xref></sup> shortly before the end of the PRoFESS trial. A graph of the network including the PRoFESS trial is displayed in <xref ref-type="fig" rid="fig2-0962280211432512">Figure 2</xref>, which shows that head-to-head comparisons for test treatment to active-control, active-control to placebo, and test treatment to placebo are available for one (PRoFESS), four and six trials, respectively. The data of the historical trials and the non-inferiority trial are shown in <xref ref-type="fig" rid="fig3-0962280211432512">Figure 3</xref>.
<fig id="fig2-0962280211432512" position="float"><label>Figure 2.</label><caption><p>Evidence network including the PRoFESS non-inferiority trial and 24 historical trials, for five treatments (Control: thienopyridine, Placebo: aspirin, Test: aspirin + dipyridamole, Active: thienopyridine + aspirin, Background therapy). The number of trials comparing two treatments is shown on the connecting line.</p></caption><graphic xlink:href="10.1177_0962280211432512-fig2.tif"/></fig>
<fig id="fig3-0962280211432512" position="float"><label>Figure 3.</label><caption><p>Data for the PRoFESS non-inferiority trial and 24 historical trials: number of events (<italic>r</italic>) and patients (<italic>n</italic>), observed proportion and 95% confidence interval. Treatments: placebo (P: aspirin), active-control (C: thienopyridine), test (T: aspirin + dipyridamole), another active treatment (A: thienopyridine + aspirin) and background therapy (B).</p></caption><graphic xlink:href="10.1177_0962280211432512-fig3.tif"/></fig></p>
<p>In the following, the NetMAP approach as described in Section 2 will be applied to the network of <xref ref-type="fig" rid="fig3-0962280211432512">Figure 3</xref>. It will be assumed that the random-effect standard deviations of the log-odds-ratios between the various treatments (T, P, A and B) and the active-control (C) are the same, which seems reasonable, as only antiplatelet agents are involved in the analysis.<sup><xref ref-type="bibr" rid="bibr44-0962280211432512">44</xref></sup></p>
<p>We will now first discuss the network meta-analysis of the 24 historical trials to assess whether the choice of the active-control group (C: thienopyridine) is justified. Since the test treatment was studied in some of the 24 historical trials, the historical data already allow comparisons between test, active-control and placebo. Second, we will use the NetMAP approach combining the historical data and the PRoFESS trial data, to evaluate whether the test treatment would have been more efficacious than placebo, had placebo been included in the non-inferiority trial.</p>
</sec>
<sec id="sec15-0962280211432512"><title>3.2.2 Analysis using historical data only</title>
<p>In a first analysis, we ignore the data from the PRoFESS trial and summarize the results for the three odds-ratios related to the test, active-control and placebo treatment based on the data from the 24 historical trials.</p>
<p>The test treatment was already studied in 7 of the 24 historical clinical trials, with 6 of them having placebo as a direct comparator. The NetMAP analysis based on the historical data <italic>Y<sub>H</sub></italic> provides already strong evidence that test treatment would be superior to placebo in a new trial. From <xref ref-type="table" rid="table4-0962280211432512">Table 4</xref>, for the odds-ratio (P vs. T), exp(<inline-formula id="ilm64-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math64-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PT</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>), the posterior median is 1.28 and <italic>P</italic>(<inline-formula id="ilm65-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math65-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> &lt; <inline-formula id="ilm66-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math66-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>|<italic>Y<sub>H</sub></italic>) = 99.4%. Due to the large network, between-trial heterogeneity can be assessed fairly precisely: it is small for the log-odds-ratios (median <italic>τ<sub>δ</sub></italic> = 0.03), whereas it is fairly substantial for the log-odds in the active-control group (median <italic>τ<sub>θ</sub></italic> = 0.44).
<table-wrap id="table4-0962280211432512" position="float"><label>Table 4.</label><caption><p>Results (posterior medians and 95% intervals) from the NetMAP analysis using 24 historical trials, with (third column) and without (second column) the PRoFESS non-inferiority trial, for three of the five treatments: thienopyridine (C), aspirin (P), aspirin + dipyridamole (T), thienopyridine + aspirin (A) and background therapy (B)</p></caption>
<graphic alternate-form-of="table4-0962280211432512" xlink:href="10.1177_0962280211432512-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Parameter</th>
<th>Historical</th>
<th>Historical and non-inferiority</th>
</tr></thead>
<tbody align="left">
<tr>
<td colspan="3"><italic>Between-trial standard deviations for log-odds-ratios (vs. C), and log-odds (C)</italic></td>
</tr>
<tr>
<td> <italic>τ<sub>δ</sub></italic></td>
<td>0.03 (0.00, 0.13)</td>
<td>0.05 (0.00, 0.14)</td>
</tr>
<tr>
<td> <italic>τ<sub>θ</sub></italic></td>
<td>0.44 (0.31, 0.64)</td>
<td>0.42 (0.30, 0.61)</td>
</tr>
<tr>
<td colspan="3"><italic>Odds-ratios and probability of superiority in PRoFESS NI trial</italic></td>
</tr>
<tr>
<td> exp(<inline-formula id="ilm67-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math67-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PT</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>)</td>
<td>1.28 (1.09, 1.50)</td>
<td>1.19 (1.01, 1.37)</td>
</tr>
<tr>
<td> Pr(T better than P)</td>
<td>99.4%</td>
<td>98.1%</td>
</tr>
<tr>
<td> exp(<inline-formula id="ilm68-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math68-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>CT</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>)</td>
<td>1.19 (0.98, 1.43)</td>
<td>1.03 (0.95, 1.11)</td>
</tr>
<tr>
<td> Pr(T better than C)</td>
<td>96.5%</td>
<td>79.5%</td>
</tr>
<tr>
<td> exp(<inline-formula id="ilm69-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math69-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>)</td>
<td>1.08 (0.93, 1.25)</td>
<td>1.15 (0.99, 1.34)</td>
</tr>
<tr>
<td> Pr(C better than P)</td>
<td>88.5%</td>
<td>97.1%</td>
</tr>
<tr>
<td colspan="3"><italic>Odds-ratios and probability of superiority for mean parameters</italic></td>
</tr>
<tr>
<td> exp(<italic>µ</italic><sub>PT</sub>)</td>
<td>1.28 (1.13, 1.45)</td>
<td>1.21 (1.09, 1.35)</td>
</tr>
<tr>
<td> Pr(T better than P)</td>
<td>99.9%</td>
<td>99.9%</td>
</tr>
<tr>
<td> exp(<italic>µ<sub>CT</sub></italic>)</td>
<td>1.19 (1.02, 1.38)</td>
<td>1.07 (0.97, 1.21)</td>
</tr>
<tr>
<td> Pr(T better than C)</td>
<td>98.5%</td>
<td>91.7%</td>
</tr>
<tr>
<td> exp(<italic>µ</italic><sub>PC</sub>)</td>
<td>1.08 (0.98, 1.20)</td>
<td>1.13 (1.02, 1.23)</td>
</tr>
<tr>
<td> Pr(C better than P)</td>
<td>93.7%</td>
<td>98.8%</td>
</tr>
</tbody>
</table>
</table-wrap></p>
<p>In the PRoFESS non-inferiority trial, the superiority of the test treatment against the active-control was also planned to be evaluated. Even though test and active-control were never directly compared in the historical trials, the NetMAP analysis provides quite strong evidence that the test treatment would be superior to active-control in a new trial: the odds-ratio exp(<inline-formula id="ilm70-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math70-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>CT</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>) has posterior median 1.19 and <italic>P</italic>(<inline-formula id="ilm71-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math71-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> &lt; <inline-formula id="ilm72-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math72-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>|<italic>Y<sub>H</sub></italic>) = 96.5%.</p>
<p>Finally, in the planned PRoFESS non-inferiority trial, thienopyridine (C) was used as the active-control (see also Fisher et al.<sup><xref ref-type="bibr" rid="bibr41-0962280211432512">41</xref></sup>). This choice of the active-control group can be considered appropriate when prior evidence is available that it would be more efficacious than placebo (P: aspirin), had placebo been included in the non-inferiority trial. The NetMAP analysis of the historical data only provides some evidence for this: exp(<inline-formula id="ilm73-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math73-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>) has posterior median 1.08 and <italic>P</italic>(<inline-formula id="ilm74-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math74-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> &lt; <inline-formula id="ilm75-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math75-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>|<italic>Y<sub>H</sub></italic>) = 88.5%.</p>
<p>In summary, based on the historical data only, the comparisons for the three treatment groups are already fairly informative. It should be noted that in this case, the historical evidence that the active-control is superior to placebo is weaker than the historical evidence that the test treatment is superior to placebo.</p>
</sec>
<sec id="sec16-0962280211432512"><title>3.2.3 NetMAP non-inferiority analysis</title>
<p>The results from the PRoFESS non-inferiority trial showed essentially identical efficacy results for the test and active-control group (1333/10151 vs. 1333/10181), which was a surprise for the medical community,<sup><xref ref-type="bibr" rid="bibr24-0962280211432512">24</xref>–<xref ref-type="bibr" rid="bibr26-0962280211432512">26</xref></sup> as historical studies seemed to suggest that the test treatment is better than the active-control.<sup><xref ref-type="bibr" rid="bibr20-0962280211432512">20</xref></sup> A network meta-analysis combining data from both the historical trials (<italic>Y<sub>H</sub></italic>) and the non-inferiority trial (<italic>Y*</italic>) still provides evidence that the test treatment would have been more efficacious than placebo in this trial: <italic>P</italic>(<inline-formula id="ilm76-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math76-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> &lt; <inline-formula id="ilm77-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math77-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>|<italic>Y<sub>H</sub></italic>, <italic>Y</italic>*) = 98.1%; this value is slightly lower than the one obtained based on the historical trials only (<xref ref-type="table" rid="table4-0962280211432512">Table 4</xref>).</p>
<p>The non-inferiority trial added information on the comparison between the placebo and the active-control as <italic>P</italic>(<inline-formula id="ilm78-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math78-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> &lt; <inline-formula id="ilm79-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math79-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>|<italic>Y<sub>H</sub></italic>, <italic>Y</italic>*) = 97.1%, i.e. considerably higher than prior to this trial: P(<inline-formula id="ilm80-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math80-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> &lt; <inline-formula id="ilm81-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math81-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>|<italic>Y<sub>H</sub></italic>) = 88.5%. Also, of interest is the updated evidence on the comparison between test and active-control including data from both the non-inferiority trial and the historical trials: P(<inline-formula id="ilm82-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math82-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> &lt; <inline-formula id="ilm83-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math83-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>|<italic>Y<sub>H</sub></italic>, <italic>Y</italic>*) = 79.5%. This is lower compared to the prior evidence: P(<inline-formula id="ilm84-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math84-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> &lt; <inline-formula id="ilm85-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math85-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>|<italic>Y<sub>H</sub></italic>) = 96.5%.</p>
<p>A graphical comparison of the different treatments before and after the results of the non-inferiority trial is shown in <xref ref-type="fig" rid="fig4-0962280211432512">Figure 4</xref>.
<fig id="fig4-0962280211432512" position="float"><label>Figure 4.</label><caption><p>NetMAP results for odds-ratios in the non-inferiority trial (median and 95% interval) based on the PRoFESS non-inferiority trial and 24 historical trials (historical + NI), or based on the historical trials only (historical).</p></caption><graphic xlink:href="10.1177_0962280211432512-fig4.tif"/></fig></p>
</sec>
<sec id="sec17-0962280211432512"><title>3.2.4 Remarks</title>
<p>
<list id="list3-0962280211432512" list-type="order">
<list-item><p>When the results of the PRoFESS non-inferiority trial were released, considerable debate on the consistency of these results with previous historical trials emerged. This discussion mainly focused on the difference between the observed odds-ratio of 1.0 for active-control vs. test in the PRoFESS trial, and the estimated population mean of the odds-ratio (1.19) derived indirectly from the historical data through a network meta-analysis.<sup><xref ref-type="bibr" rid="bibr20-0962280211432512">20</xref></sup> Salanti et al.<sup><xref ref-type="bibr" rid="bibr44-0962280211432512">44</xref></sup> argued that the apparent discrepancy is mainly due to misinterpretation and lack of adequate communication of the results of the network meta-analysis.</p></list-item>
</list></p>
<p>To properly assess possible discrepancies between the results from the non-inferiority trial and the analysis based on the historical trials, the observed odds-ratio in the PRoFESS trial should be compared with the predictive distribution of the observed odds-ratio, rather than with the model-based parameters (population mean or predicted effect). That is, the relevant predictive distribution is
<disp-formula id="disp-formula16-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math16-0962280211432512"><mml:mrow><mml:mtext>Pr</mml:mtext><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mo>|</mml:mo><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo/></mml:mrow></mml:mrow></mml:math><graphic alternate-form-of="disp-formula16-0962280211432512" xlink:href="10.1177_0962280211432512-eq16.tif"/></disp-formula>
 where <italic>n<sub>T</sub></italic> and <italic>n<sub>C</sub></italic> are the number of patients in the PRoFESS trial. In this way, sampling variability, parameter uncertainty and between-trial variability are accounted for. The resulting probability that an OR of 1 (as seen in the PRoFESS trial) or lower will be observed in the non-inferiority trial is 4.5%. Although this value is rather low, it does not provide compelling evidence for a discrepancy between the historical data and the results from the non-inferiority trial.
<list id="list4-0962280211432512" list-type="order">
<list-item><p>The test treatment was already studied in several of the historical trials, and this information was used in the network meta-analysis, integrating data from both the non-inferiority trial and the historical trials. When the test treatment in the PRoFESS non-inferiority trial is considered as a another (sixth) treatment (different from the test treatment in the historical trials), then the evidence that the test treatment would have been superior to placebo in the PRoFESS trial is less clear, namely 85.0%, than when all the available information is used (98.1%).This is due to the not fully convincing historical evidence that the active-control is better than placebo.</p></list-item>
<list-item><p>In the NetMAP analysis, the log-odds of the event probabilities in the active-control group were modelled by random-effects. The results are only minimally changed when the active-control event probabilities are considered as unrelated (results not shown). For example, the odds-ratio comparing placebo with test in the non-inferiority trial is 1.18 (1.00, 1.37), with a posterior probability that test is better than placebo of 97.7%. As more than 10 000 patients were randomized to the active-control arm of the non-inferiority trial, the additional information gained using a random-effect model for the active-control event probabilities is very small.</p></list-item>
<list-item><p>The PRoFESS non-inferiority trial was evaluated based on the so-called fixed margin approach, discussed in Section 4. Despite the equal event proportions observed in the ProFESS trial for test and active-control and the very large number of patients included, the trial did not meet the criteria for non-inferiority.<sup><xref ref-type="bibr" rid="bibr23-0962280211432512">23</xref></sup></p></list-item>
</list></p>
</sec>
</sec>
</sec>
<sec id="sec18-0962280211432512"><title>4 Other approaches</title>
<p>Although regulatory guidance on non-inferiority trials is available,<sup><xref ref-type="bibr" rid="bibr9-0962280211432512">9</xref>,<xref ref-type="bibr" rid="bibr10-0962280211432512">10</xref></sup> the topic is still controversial as highlighted by the many comments to the recently released draft guidance by the Food and Drug Adminstration,<sup><xref ref-type="bibr" rid="bibr11-0962280211432512">11</xref></sup> which discusses two approaches: the ‘synthesis approach’ and the ‘fixed margin approach’. In the synthesis approach, it is assumed that between-trial variability of the treatment differences is negligible; pragmatic reasons for making this ‘constancy assumption’ are suggested in Fisher et al.<sup><xref ref-type="bibr" rid="bibr41-0962280211432512">41</xref></sup> The synthesis method fully relies on this assumption and derives an efficient statistical test which indirectly compares the test treatment with placebo. As the ‘constancy assumption’ is often unrealistic, the fixed margin approach has been proposed as a conservative procedure. However, the fixed margin approach is very inefficient,<sup><xref ref-type="bibr" rid="bibr45-0962280211432512">45</xref></sup> may lead to logical inconsistencies,<sup><xref ref-type="bibr" rid="bibr46-0962280211432512">46</xref>,<xref ref-type="bibr" rid="bibr47-0962280211432512">47</xref></sup> and does not directly address the invalidity of the constancy assumption.<sup><xref ref-type="bibr" rid="bibr43-0962280211432512">43</xref></sup></p>
<sec id="sec19-0962280211432512"><title>4.1 Synthesis approach</title>
<p>The synthesis method<sup><xref ref-type="bibr" rid="bibr12-0962280211432512">12</xref>,<xref ref-type="bibr" rid="bibr41-0962280211432512">41</xref>,<xref ref-type="bibr" rid="bibr48-0962280211432512">48</xref></sup> aims to indirectly estimate the population mean difference between test treatment and placebo (<italic>µ<sub>T</sub><sub>P</sub></italic>). A 95% confidence interval for <italic>µ<sub>TP</sub></italic> is derived, and the test treatment is considered to be superior to placebo if the upper limit of this confidence interval is less than zero (assuming that low event proportions correspond to better efficacy). The method is based on the additivity (on an appropriate scale) of the population mean differences for test, active-control and placebo treatment: <italic>µ<sub>TP</sub></italic> = <italic>µ<sub>TC</sub></italic> − <italic>µ<sub>PC</sub></italic>; this relationship holds, for example, for the generalized mixed model described in Section 2. An estimate for <italic>µ<sub>TC</sub></italic> is obtained from the non-inferiority trial, and an estimate for <italic>µ<sub>PC</sub></italic> can be derived from a meta-analysis of the historical trials comparing the active-control and placebo. The population mean difference between test treatment and placebo is then estimated by the difference of these independent estimates for <italic>µ<sub>TC</sub></italic> and <italic>µ<sub>PC</sub></italic>.</p>
<p>It should be noted that the difference of test treatment and placebo for the non-inferiority trial (<inline-formula id="ilm86-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math86-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TP</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>) is of central interest, rather than the population mean difference (<italic>µ<sub>T</sub><sub>P</sub></italic>). In the synthesis approach, the key assumption is that there is no between-trial variability of the treatment differences (<italic>τ<sub>δ</sub></italic> = 0). Under this constancy assumption, <inline-formula id="ilm87-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math87-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TP</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> is identical to <italic>µ<sub>TP</sub></italic>, and hence inference can be based on <italic>µ<sub>TP</sub></italic>. If the assumption of no between-trial variability in treatment differences is not correct, then the synthesis approach is not valid.<sup><xref ref-type="bibr" rid="bibr45-0962280211432512">45</xref></sup></p>
</sec>
<sec id="sec20-0962280211432512"><title>4.2 Fixed margin approach</title>
<p>The synthesis approach evaluates whether the difference between test treatment and putative placebo is less than zero: <italic>µ<sub>TP</sub></italic> &lt; 0 vs. <italic>µ<sub>TP</sub></italic> ≥ 0. As <italic>µ<sub>TP</sub></italic> = <italic>µ<sub>TC</sub></italic> − <italic>µ<sub>PC</sub></italic>, this is equivalent to: <italic>µ<sub>TC</sub></italic> &lt; <italic>µ<sub>PC</sub></italic> vs. <italic>µ<sub>TC</sub></italic> ≥ <italic>µ<sub>P</sub><sub>C</sub></italic>. The fixed margin approach<sup><xref ref-type="bibr" rid="bibr6-0962280211432512">6</xref>,<xref ref-type="bibr" rid="bibr45-0962280211432512">45</xref></sup> is a two-stage procedure to evaluate whether <italic>µ<sub>TC</sub></italic> is less than <italic>µ<sub>PC</sub></italic>. First, a non-inferiority margin <italic>M</italic> is chosen such that one is confident that <italic>µ<sub>PC</sub></italic> ≥ <italic>M</italic>; the margin is considered as a fixed number. Second, it is evaluated whether <italic>µ<sub>TC</sub></italic> &lt; <italic>M</italic>. This is done by deriving a 95% confidence interval for <italic>µ<sub>TC</sub></italic> based on the data from the non-inferiority trial. If the upper limit of this confidence interval is less than <italic>M</italic>, then the test treatment is considered to be non-inferior to the active-control.</p>
<p>Historically, the margin <italic>M</italic> was typically defined by medical experts. A more objective approach to the choice of the margin is based on a meta-analysis of historical trials comparing the placebo with the active-control. From the meta-analysis, a 95% confidence interval for <italic>µ<sub>PC</sub></italic> is derived, and the non-inferiority margin <italic>M</italic> is then the lower limit of the confidence interval (representing an optimistic effect for placebo). Confidence levels such as 90% or 80% are also sometimes used. Often, the non-inferiority margin derived from the meta-analysis is then further reduced by a so-called preservation factor, again introducing medical judgment.</p>
<p>The procedure is graphically illustrated in <xref ref-type="fig" rid="fig5-0962280211432512">Figure 5</xref> for the ESSENCE non-inferiority trial of Section 3.1. We first note that the 95% interval derived from the historical data for the population log-odds-ratio (<italic>µ<sub>PC</sub></italic>) includes zero (<xref ref-type="table" rid="table3-0962280211432512">Table 3</xref>); hence, no non-inferiority margin <italic>M</italic> can be derived for this confidence level. Alternatively, if an 80% interval for <italic>µ<sub>PC</sub></italic> is considered to be appropriate, then a non-inferiority margin for the population odds-ratio of <italic>M</italic> = 1.14 is obtained. The upper limit of the 95% interval for the odds-ratio of test against active-control from the non-inferiority trial is 1.03. As this is lower than the non-inferiority margin <italic>M</italic>, the test treatment would be declared non-inferior to the active-control.
<fig id="fig5-0962280211432512" position="float"><label>Figure 5.</label><caption><p>Non-inferiority margin approach for the ESSENCE non-inferiority trial, and six historical trials. Margins based on population mean parameter <italic>µ<sub>PC</sub></italic> (<italic>M</italic> = 1.14) or the parameter in the non-inferiority trial <inline-formula id="ilm88-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math88-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> (<italic>M</italic>* = 1.03) are shown as horizontal dotted lines.</p></caption><graphic xlink:href="10.1177_0962280211432512-fig5.tif"/></fig></p>
<p>It should be noted that in the calculation of the non-inferiority margin, a confidence interval for the population log-odds-ratio (<italic>µ<sub>PC</sub></italic>) rather than for the predicted log-odds-ratio in the non-inferiority trial (<inline-formula id="ilm89-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math89-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>) is used. The two quantities are only identical if the between-trial variability <italic>τ<sub>δ</sub></italic> is negligible. When the between-trial variability <italic>τ<sub>δ</sub></italic> is not assumed to be zero, then a non-inferiority margin based on <inline-formula id="ilm90-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math90-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>PC</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> seems more appropriate; in this case, where an 80% confidence level is considered, a non-inferiority margin of <italic>M</italic>* = 1.03 would be obtained (<xref ref-type="fig" rid="fig5-0962280211432512">Figure 5</xref>). The upper limit of the 95% interval for the odds-ratio of test treatment against active-control from the non-inferiority trial would then be equal to the margin <italic>M</italic>* – a borderline result.</p>
</sec>
</sec>
<sec id="sec21-0962280211432512" sec-type="discussions"><title>5 Discussion</title>
<p>The interpretation and evaluation of non-inferiority trials is challenging as it involves indirect comparisons to historical information. We have focused here on the main statistical question, namely whether the test treatment would have shown superior efficacy to placebo, had placebo been used in the non-inferiority trial.</p>
<p>One may ask why one should not require superiority of the test treatment to the active-control, which would allow a direct comparison within the non-inferiority trial and avoid some of the interpretational issues. There are several reasons why this is often not appropriate. For example, the test treatment may be better tolerated by patients than the active-control, have a better safety profile, be more convenient (e.g. tablet vs. infusion) or may be less expensive. In these situations, equal or less efficacy of the test compared to active-control may be acceptable, as long as there is (indirect) evidence of its superiority to placebo.</p>
<p>Here, we have not covered the choice of an appropriate sample size in the planning of a non-inferiority trial, as methods described in Simon<sup><xref ref-type="bibr" rid="bibr22-0962280211432512">22</xref></sup> can be adapted to the framework presented here. We note that results of a network meta-analysis of the historical data may also be used in the planning of a non-inferiority trial based on a fixed margin approach.<sup><xref ref-type="bibr" rid="bibr49-0962280211432512">49</xref></sup></p>
<p>In this article, we have focused on binary endpoints, as these are common in clinical trials. However, extensions to other endpoints such as normally or Poisson distributed endpoints are straightforward, as the network meta-analysis models are still within the class of generalized linear mixed models. Methods to handle time-to-event endpoints in network meta-analysis have also been developed.<sup><xref ref-type="bibr" rid="bibr50-0962280211432512">50</xref></sup> Relevant covariate information for the treatment arms in both the non-inferiority trial and the historical trials can also be integrated, and may explain part of the between-trial variability. In many therapeutic areas such as transplantation or oncology, drug combinations are common. Assuming additivity of the contributions of the individual drugs, a generalized linear mixed model is again obtained.<sup><xref ref-type="bibr" rid="bibr51-0962280211432512">51</xref></sup></p>
<p>For the indirect comparison of test treatment to placebo, a statistical model was transparently used to link non-inferiority trial and historical trials in a common network of evidence. As with every statistical model, both scientific judgment and model validation<sup><xref ref-type="bibr" rid="bibr17-0962280211432512">17</xref>,<xref ref-type="bibr" rid="bibr18-0962280211432512">18</xref>,<xref ref-type="bibr" rid="bibr52-0962280211432512">52</xref></sup> are necessary to determine its appropriateness.</p>
<p>The main feature of the NetMAP approach is the prediction of the putative test vs. placebo effect in the NI trial (<inline-formula id="ilm91-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math91-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TP</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>) rather than the estimation of the population mean effect (<italic>µ<sub>T</sub><sub>P</sub></italic>) while allowing for between-trial variation. That the predictive aspect is important can be seen from standard calculus for the simplest meta-analytic setting with approximately normally distributed data and known between-trial variance <italic>τ</italic><sup>2</sup>, from which it follows that
<disp-formula id="disp-formula17-0962280211432512"><label>(6)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math17-0962280211432512"><mml:mrow><mml:mtext>Var</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TP</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mtext>Var</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi>TP</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><graphic alternate-form-of="disp-formula17-0962280211432512" xlink:href="10.1177_0962280211432512-eq17.tif"/></disp-formula>
</p>
<p>Here, in the classical setting, the variances refer to the estimates for the two parameters, and in the Bayesian setting, posterior variances apply. <xref ref-type="disp-formula" rid="disp-formula15-0962280211432512">Equation (6)</xref> makes the crucial difference between the two parameters clear: a statement about the putative T vs. P effect <inline-formula id="ilm92-0962280211432512"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math92-0962280211432512"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mi>TP</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> in the NI trial is genuinely predictive and therefore fairly uncertain if between-trial heterogeneity is present. This is not so for the population mean parameter <italic>µ<sub>T</sub><sub>P</sub></italic>, because this parameter can be estimated precisely if the amount of historical data is large. The considerable impact of accounting for between-trial variability with regard to discounting external information is well known when deriving prior distributions from historical data.<sup><xref ref-type="bibr" rid="bibr32-0962280211432512">32</xref>,<xref ref-type="bibr" rid="bibr53-0962280211432512">53</xref>–<xref ref-type="bibr" rid="bibr56-0962280211432512">56</xref></sup></p>
<p>Given the unavoidable complexity of a model that accounts for between-trial heterogeneity for three (or more) treatments, several historical trials and the non-inferiority trial, it is advisable to clearly specify assumptions and to check the robustness of conclusions for these assumptions, which relate to different factors.</p>
<p>First, what is included in the historical database is probably the most important factor, due to the indirect evidence arising from these data when quantifying the active-control vs. placebo effect and, ultimately, the test vs. placebo effect in the non-inferiority trial.<sup><xref ref-type="bibr" rid="bibr57-0962280211432512">57</xref>,<xref ref-type="bibr" rid="bibr58-0962280211432512">58</xref></sup></p>
<p>Second, the sampling model should be considered carefully, with regard to the choice of outcome (e.g. approximate normal vs. binary vs. time-to-event), and the availability of important covariates that may be predictive and could reduce between-trial heterogeneity. Of course, the criticality of a reasonable sampling model is a common theme in statistics and goes beyond the evaluation of non-inferiority trials.</p>
<p>Third, the assumptions for the parametric model, such as fixed vs. random-effects for active-control parameters (log-odds) or common vs. random-effects for treatment effects (log-odds-ratios) may influence conclusions. Model checking <italic>via</italic> residual analyses or posterior predictive checks and model comparisons <italic>via</italic> the deviance information criterion<sup><xref ref-type="bibr" rid="bibr59-0962280211432512">59</xref></sup> are useful tools to separate the wheat from the chaff.</p>
<p>And fourth, the choice of the inferential approach (likelihood or Bayesian) may lead to different conclusions although, if done well, differences in results should be small. Challenges for the two paradigms remain: in the likelihood setting, it is the appropriate handling of uncertainties for between-trial standard deviations, which clearly should go beyond the naive use of plug-in estimates (which are often zero despite considerable uncertainty), or homogeneity tests (which have notoriously low power), while in the Bayesian setting reasonable prior specifications are important.</p>
<p>The different approaches to interpretation and evaluation of non-inferiority trials will remain controversial.<sup><xref ref-type="bibr" rid="bibr60-0962280211432512">60</xref></sup> We think this is mainly due to the fact that formally synthesizing evidence from different sources (which seems unavoidable in the non-inferiority setting) goes beyond standard approaches to confirmatory clinical trials. Two major challenges in evidence synthesis are what and how to synthesize. The NetMAP approach we have discussed here has addressed the latter (and easier) of the two, in a Bayesian framework. The former question as to what constitutes relevant contextual information is also inherently Bayesian in that it relates to the relevant prior information, which will always be situation-specific and require good judgment. These considerations seem to agree well with a statement by Sue Ellenberg (FDA): ‘I think that the area of noninferiority trials is one that really lends itself to the Bayesian approach’.<sup><xref ref-type="bibr" rid="bibr61-0962280211432512">61</xref></sup></p>
</sec>
</body>
<back><ack>
<title>Acknowledgements</title>
<p>The authors would like to thank an anonymous reviewer for helpful comments.</p></ack>
<ref-list>
<title>References</title>
<ref id="bibr1-0962280211432512"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Temple</surname><given-names>R</given-names></name><name><surname>Ellenberg</surname><given-names>SS</given-names></name></person-group>. <article-title>Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues</article-title>. <source>Ann Intern Med</source> <year>2000</year>; <volume>133</volume>(<issue>6</issue>): <fpage>455</fpage>–<lpage>463</lpage>.</citation></ref>
<ref id="bibr2-0962280211432512"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ellenberg</surname><given-names>SS</given-names></name><name><surname>Temple</surname><given-names>R</given-names></name></person-group>. <article-title>Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases</article-title>. <source>Ann Intern Med</source> <year>2000</year>; <volume>133</volume>(<issue>6</issue>): <fpage>464</fpage>–<lpage>470</lpage>.</citation></ref>
<ref id="bibr3-0962280211432512"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>JA</given-names></name></person-group>. <article-title>The European regulatory experience</article-title>. <source>Stat Med</source> <year>2002</year>; <volume>21</volume>(<issue>19</issue>): <fpage>2931</fpage>–<lpage>2938</lpage>.</citation></ref>
<ref id="bibr4-0962280211432512"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>B</given-names></name><name><surname>Jarvis</surname><given-names>P</given-names></name><name><surname>Lewis</surname><given-names>JA</given-names></name><name><surname>Ebbutt</surname><given-names>AF</given-names></name></person-group>. <article-title>Trials to assess equivalence: the importance of rigorous methods</article-title>. <source>Br Med J</source> <year>1996</year>; <volume>313</volume>(<issue>7048</issue>): <fpage>36</fpage>–<lpage>39</lpage>.</citation></ref>
<ref id="bibr5-0962280211432512"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ellenberg</surname><given-names>SS</given-names></name></person-group>. <article-title>Scientific and ethical issues in the use of placebo and active controls in clinical trials</article-title>. <source>J Bone Miner Res</source> <year>2003</year>; <volume>18</volume>(<issue>6</issue>): <fpage>1121</fpage>–<lpage>1124</lpage>.</citation></ref>
<ref id="bibr6-0962280211432512"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>HM</given-names></name><name><surname>Wang</surname><given-names>SJ</given-names></name><name><surname>O’Neill</surname><given-names>R</given-names></name></person-group>. <article-title>Challenges and regulatory experiences with non-inferiority trial design without placebo arm</article-title>. <source>Biometrical J</source> <year>2009</year>; <volume>51</volume>(<issue>2</issue>): <fpage>324</fpage>–<lpage>334</lpage>.</citation></ref>
<ref id="bibr7-0962280211432512"><label>7</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Whitehead</surname><given-names>A</given-names></name></person-group>. <source>Meta-analysis of controlled clinical trials</source>, <publisher-loc>New York, NY</publisher-loc>: <publisher-name>John Wiley &amp; Sons</publisher-name>, <year>2002</year>.</citation></ref>
<ref id="bibr8-0962280211432512"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name><name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name></person-group>. <article-title>A re-evaluation of random-effects meta-analysis</article-title>. <source>J Royal Stat Soc Ser A</source> <year>2009</year>; <volume>172</volume>(<issue>1</issue>): <fpage>137</fpage>–<lpage>159</lpage>.</citation></ref>
<ref id="bibr9-0962280211432512"><label>9</label><citation citation-type="other"><comment>ICH E10. <italic>Choice of control group in clinical trials</italic>. London: European Agency for the Evaluation of Medicinal Products, CPMP/ICH/364/396, <ext-link ext-link-type="uri" xlink:href="http://www.ich.org/LOB/media/MEDIA486.pdf">http://www.ich.org/LOB/media/MEDIA486.pdf</ext-link> (2000, accessed January 2011)</comment>.</citation></ref>
<ref id="bibr10-0962280211432512"><label>10</label><citation citation-type="other"><comment>CHMP. <italic>Guideline for the choice of non-inferiority margin</italic>. London: European Medicines Agency, EMEA/CPMP/EWP/2158/99, <ext-link ext-link-type="uri" xlink:href="http://www.emea.europa.eu/pdfs/human/ewp/215899en.pdf">http://www.emea.europa.eu/pdfs/human/ewp/215899en.pdf</ext-link> (2005, accessed January 2011)</comment>.</citation></ref>
<ref id="bibr11-0962280211432512"><label>11</label><citation citation-type="other"><comment>FDA. <italic>Draft guidance for industry: non-inferiority clinical trials</italic>. Silver Spring, MD: FDA, <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/Drugs/">http://www.fda.gov/downloads/Drugs/</ext-link> GuidanceComplianceRegulatoryInformation/Guidances/UCM202140.pdf (2010, accessed January 2011)</comment>.</citation></ref>
<ref id="bibr12-0962280211432512"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hasselblad</surname><given-names>V</given-names></name><name><surname>Kong</surname><given-names>DF</given-names></name></person-group>. <article-title>Statistical methods for comparison to placebo in active-control trials</article-title>. <source>Drug Inf J</source> <year>2001</year>; <volume>35</volume>: <fpage>435</fpage>–<lpage>449</lpage>.</citation></ref>
<ref id="bibr13-0962280211432512"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Whitehead</surname><given-names>A</given-names></name></person-group>. <article-title>Borrowing strength from external trials in a meta-analysis</article-title>. <source>Stat Med</source> <year>1996</year>; <volume>15</volume>(<issue>24</issue>): <fpage>2733</fpage>–<lpage>2749</lpage>.</citation></ref>
<ref id="bibr14-0962280211432512"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hasselblad</surname><given-names>V</given-names></name></person-group>. <article-title>Meta-analysis of multitreatment studies</article-title>. <source>Med Decis Making</source> <year>1998</year>; <volume>18</volume>: <fpage>37</fpage>–<lpage>43</lpage>.</citation></ref>
<ref id="bibr15-0962280211432512"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lumley</surname><given-names>T</given-names></name></person-group>. <article-title>Network meta-analysis for indirect treatment comparisons</article-title>. <source>Stat Med</source> <year>2002</year>; <volume>21</volume>(<issue>16</issue>): <fpage>2313</fpage>–<lpage>2324</lpage>.</citation></ref>
<ref id="bibr16-0962280211432512"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Ades</surname><given-names>AE</given-names></name></person-group>. <article-title>Combination of direct and indirect evidence in mixed treatment comparisons</article-title>. <source>Stat Med</source> <year>2004</year>; <volume>23</volume>(<issue>20</issue>): <fpage>3105</fpage>–<lpage>3124</lpage>.</citation></ref>
<ref id="bibr17-0962280211432512"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Ades</surname><given-names>AE</given-names></name></person-group>. <article-title>Assessing evidence inconsistency in mixed treatment comparisons</article-title>. <source>J Am Stat Assoc</source> <year>2006</year>; <volume>101</volume>(<issue>474</issue>): <fpage>447</fpage>–<lpage>459</lpage>.</citation></ref>
<ref id="bibr18-0962280211432512"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salanti</surname><given-names>G</given-names></name><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Ades</surname><given-names>AE</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name></person-group>. <article-title>Evaluation of networks of randomized trials</article-title>. <source>Stat Methods Med Res</source> <year>2008</year>; <volume>17</volume>(<issue>3</issue>): <fpage>279</fpage>–<lpage>301</lpage>.</citation></ref>
<ref id="bibr19-0962280211432512"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nixon</surname><given-names>RM</given-names></name><name><surname>Bansback</surname><given-names>N</given-names></name><name><surname>Brennan</surname><given-names>A</given-names></name></person-group>. <article-title>Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis</article-title>. <source>Stat Med</source> <year>2007</year>; <volume>26</volume>(<issue>6</issue>): <fpage>1237</fpage>–<lpage>1254</lpage>.</citation></ref>
<ref id="bibr20-0962280211432512"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thijs</surname><given-names>V</given-names></name><name><surname>Lemmens</surname><given-names>R</given-names></name><name><surname>Fieuws</surname><given-names>S</given-names></name></person-group>. <article-title>Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke</article-title>. <source>Eur Heart J</source> <year>2008</year>; <volume>29</volume>(<issue>9</issue>): <fpage>1086</fpage>–<lpage>1092</lpage>.</citation></ref>
<ref id="bibr21-0962280211432512"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wandel</surname><given-names>S</given-names></name><name><surname>Jüni</surname><given-names>P</given-names></name><name><surname>Tendal</surname><given-names>B</given-names></name><name><surname>Nüesch</surname><given-names>E</given-names></name><name><surname>Villiger</surname><given-names>PM</given-names></name><name><surname>Welton</surname><given-names>NJ</given-names></name><etal/></person-group>. <article-title>Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis</article-title>. <source>Br Med J</source> <year>2010</year>; <volume>341</volume>: <fpage>c4675</fpage>–<lpage>c4675</lpage>.</citation></ref>
<ref id="bibr22-0962280211432512"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>R</given-names></name></person-group>. <article-title>Bayesian design and analysis of active control clinical trials</article-title>. <source>Biometrics</source> <year>1999</year>; <volume>55</volume>(<issue>2</issue>): <fpage>484</fpage>–<lpage>487</lpage>.</citation></ref>
<ref id="bibr23-0962280211432512"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sacco</surname><given-names>RL</given-names></name><name><surname>Diener</surname><given-names>HC</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Cotton</surname><given-names>D</given-names></name><name><surname>Ounpuu</surname><given-names>S</given-names></name><name><surname>Lawton</surname><given-names>WA</given-names></name><etal/></person-group>. <article-title>Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke</article-title>. <source>N Engl J Med</source> <year>2008</year>; <volume>359</volume>(<issue>12</issue>): <fpage>1238</fpage>–<lpage>1251</lpage>.</citation></ref>
<ref id="bibr24-0962280211432512"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname><given-names>DM</given-names></name><name><surname>Thaler</surname><given-names>DE</given-names></name></person-group>. <article-title>Stroke prevention–insights from incoherence</article-title>. <source>N Engl J Med</source> <year>2008</year>; <volume>359</volume>(<issue>12</issue>): <fpage>1287</fpage>–<lpage>1289</lpage>.</citation></ref>
<ref id="bibr25-0962280211432512"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Biller</surname><given-names>J</given-names></name></person-group>. <article-title>Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy</article-title>. <source>J Neurol Sci</source> <year>2009</year>; <volume>284</volume>(<issue>1–2</issue>): <fpage>1</fpage>–<lpage>9</lpage>.</citation></ref>
<ref id="bibr26-0962280211432512"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Algra</surname><given-names>A</given-names></name></person-group>. <article-title>Digestion of the antiplatelets comparison of PRoFESS: 18-7=1?</article-title> <source>Stroke</source> <year>2009</year>; <volume>40</volume>(<issue>5</issue>): <fpage>1932</fpage>–<lpage>1935</lpage>.</citation></ref>
<ref id="bibr27-0962280211432512"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Ades</surname><given-names>AE</given-names></name><name><surname>Sutton</surname><given-names>AJ</given-names></name><name><surname>Cooper</surname><given-names>NJ</given-names></name><name><surname>Briggs</surname><given-names>AH</given-names></name><name><surname>Caldwell</surname><given-names>DM</given-names></name></person-group>. <article-title>Meta-analysis of mixed treatment comparisons at multiple follow-up times</article-title>. <source>Stat Med</source> <year>2007</year>; <volume>26</volume>(<issue>20</issue>): <fpage>3681</fpage>–<lpage>3699</lpage>.</citation></ref>
<ref id="bibr28-0962280211432512"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pocock</surname><given-names>SJ</given-names></name></person-group>. <article-title>The combination of randomized and historical controls in clinical trials</article-title>. <source>J Chronic Dis</source> <year>1976</year>; <volume>29</volume>(<issue>3</issue>): <fpage>175</fpage>–<lpage>188</lpage>.</citation></ref>
<ref id="bibr29-0962280211432512"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carlin</surname><given-names>JB</given-names></name></person-group>. <article-title>Letter to the editor</article-title>. <source>Stat Med</source> <year>2000</year>; <volume>19</volume>(<issue>5</issue>): <fpage>753</fpage>–<lpage>759</lpage>.</citation></ref>
<ref id="bibr30-0962280211432512"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Houwelingen</surname><given-names>HC</given-names></name><name><surname>Arends</surname><given-names>LR</given-names></name><name><surname>Stijnen</surname><given-names>T</given-names></name></person-group>. <article-title>Advanced methods in meta-analysis: multivariate approach and meta-regression</article-title>. <source>Stat Med</source> <year>2002</year>; <volume>21</volume>(<issue>4</issue>): <fpage>589</fpage>–<lpage>624</lpage>.</citation></ref>
<ref id="bibr31-0962280211432512"><label>31</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Gelman</surname><given-names>A</given-names></name><name><surname>Carlin</surname><given-names>JB</given-names></name><name><surname>Stern</surname><given-names>HS</given-names></name><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group>. <source>Bayesian data analysis</source>, <edition>2nd ed</edition>. <publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>CRC Press</publisher-name>, <year>2004</year>.</citation></ref>
<ref id="bibr32-0962280211432512"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neuenschwander</surname><given-names>B</given-names></name><name><surname>Capkun-Niggli</surname><given-names>G</given-names></name><name><surname>Branson</surname><given-names>M</given-names></name><name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name></person-group>. <article-title>Summarizing historical information on controls in clinical trials</article-title>. <source>Clin Trials</source> <year>2010</year>; <volume>7</volume>(<issue>1</issue>): <fpage>5</fpage>–<lpage>18</lpage>.</citation></ref>
<ref id="bibr33-0962280211432512"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stijnen</surname><given-names>T</given-names></name><name><surname>Hamza</surname><given-names>TH</given-names></name><name><surname>Ozdemir</surname><given-names>P</given-names></name></person-group>. <article-title>Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data</article-title>. <source>Stat Med</source> <year>2010</year>; <volume>29</volume>(<issue>29</issue>): <fpage>3046</fpage>–<lpage>3067</lpage>.</citation></ref>
<ref id="bibr34-0962280211432512"><label>34</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name><name><surname>Abrams</surname><given-names>KR</given-names></name><name><surname>Myles</surname><given-names>JP</given-names></name></person-group>. <source>Bayesian approaches to clinical trials and health-care evaluation</source>, <publisher-loc>New York, NY</publisher-loc>: <publisher-name>John Wiley &amp; Sons</publisher-name>, <year>2004</year>.</citation></ref>
<ref id="bibr35-0962280211432512"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gelman</surname><given-names>A</given-names></name></person-group>. <article-title>Prior distributions for variance parameters in hierarchical models</article-title>. <source>Bayesian Analysis</source> <year>2006</year>; <volume>1</volume>: <fpage>515</fpage>–<lpage>533</lpage>.</citation></ref>
<ref id="bibr36-0962280211432512"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pullenayegum</surname><given-names>EM</given-names></name></person-group>. <article-title>An informed reference prior for between-study heterogeneity in meta-analyses of binary outcomes</article-title>. <source>Stat Med</source> <year>2011</year>; <volume>30</volume>(<issue>26</issue>): <fpage>3082</fpage>–<lpage>3094</lpage>.</citation></ref>
<ref id="bibr37-0962280211432512"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gelfand</surname><given-names>AE</given-names></name><name><surname>Smith</surname><given-names>AFM</given-names></name></person-group>. <article-title>Sampling-based approaches to calculating marginal densities</article-title>. <source>J Am Stat Assoc</source> <year>1990</year>; <volume>85</volume>: <fpage>398</fpage>–<lpage>409</lpage>.</citation></ref>
<ref id="bibr38-0962280211432512"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lunn</surname><given-names>DJ</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Best</surname><given-names>N</given-names></name><name><surname>Spiegelhalter</surname><given-names>D</given-names></name></person-group>. <article-title>WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility</article-title>. <source>Stat Comput</source> <year>2000</year>; <volume>10</volume>: <fpage>325</fpage>–<lpage>337</lpage>.</citation></ref>
<ref id="bibr39-0962280211432512"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>M</given-names></name><name><surname>Demers</surname><given-names>C</given-names></name><name><surname>Gurfinkel</surname><given-names>EP</given-names></name><name><surname>Turpie</surname><given-names>AG</given-names></name><name><surname>Fromell</surname><given-names>GJ</given-names></name><name><surname>Goodman</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events</article-title>. <source>Am J Cardiol</source> <year>1998</year>; <volume>82</volume>(<issue>5B</issue>): <fpage>19L</fpage>–<lpage>24L</lpage>.</citation></ref>
<ref id="bibr40-0962280211432512"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oler</surname><given-names>A</given-names></name><name><surname>Whooley</surname><given-names>MA</given-names></name><name><surname>Oler</surname><given-names>J</given-names></name><name><surname>Grady</surname><given-names>D</given-names></name></person-group>. <article-title>Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis</article-title>. <source>JAMA</source> <year>1996</year>; <volume>276</volume>(<issue>10</issue>): <fpage>811</fpage>–<lpage>815</lpage>.</citation></ref>
<ref id="bibr41-0962280211432512"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>LD</given-names></name><name><surname>Gent</surname><given-names>M</given-names></name><name><surname>Büller</surname><given-names>HR</given-names></name></person-group>. <article-title>Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo</article-title>. <source>Am Heart J</source> <year>2001</year>; <volume>141</volume>(<issue>1</issue>): <fpage>26</fpage>–<lpage>32</lpage>.</citation></ref>
<ref id="bibr42-0962280211432512"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Durrleman</surname><given-names>S</given-names></name><name><surname>Chaikin</surname><given-names>P</given-names></name></person-group>. <article-title>The use of putative placebo in active control trials: two applications in a regulatory setting</article-title>. <source>Stat Med</source> <year>2003</year>; <volume>22</volume>(<issue>6</issue>): <fpage>941</fpage>–<lpage>952</lpage>.</citation></ref>
<ref id="bibr43-0962280211432512"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>TR</given-names></name></person-group>. <article-title>Current issues in non-inferiority trials</article-title>. <source>Stat Med</source> <year>2008</year>; <volume>27</volume>(<issue>3</issue>): <fpage>317</fpage>–<lpage>332</lpage>.</citation></ref>
<ref id="bibr44-0962280211432512"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salanti</surname><given-names>G</given-names></name><name><surname>Ades</surname><given-names>AE</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name></person-group>. <article-title>Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial</article-title>. <source>J Clin Epidemiol</source> <year>2011</year>; <volume>64</volume>(<issue>2</issue>): <fpage>163</fpage>–<lpage>171</lpage>.</citation></ref>
<ref id="bibr45-0962280211432512"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>SJ</given-names></name><name><surname>Hung</surname><given-names>HM</given-names></name><name><surname>Tsong</surname><given-names>Y</given-names></name></person-group>. <article-title>Utility and pitfalls of some statistical methods in active controlled clinical trials</article-title>. <source>Control Clin Trials</source> <year>2002</year>; <volume>23</volume>(<issue>1</issue>): <fpage>15</fpage>–<lpage>28</lpage>.</citation></ref>
<ref id="bibr46-0962280211432512"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Senn</surname><given-names>SJ</given-names></name></person-group>. <article-title>‘Equivalence is different’ - some comments on therapeutic equivalence</article-title>. <source>Biometrical J</source> <year>2005</year>; <volume>47</volume>: <fpage>104</fpage>–<lpage>107</lpage>.</citation></ref>
<ref id="bibr47-0962280211432512"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Snapinn</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>Q</given-names></name></person-group>. <article-title>Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials</article-title>. <source>Stat Med</source> <year>2008</year>; <volume>27</volume>(<issue>3</issue>): <fpage>382</fpage>–<lpage>391</lpage>.</citation></ref>
<ref id="bibr48-0962280211432512"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rothmann</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Chi</surname><given-names>GY</given-names></name><name><surname>Temple</surname><given-names>R</given-names></name><name><surname>Tsou</surname><given-names>HH</given-names></name></person-group>. <article-title>Design and analysis of non-inferiority mortality trials in oncology</article-title>. <source>Stat Med</source> <year>2003</year>; <volume>22</volume>(<issue>2</issue>): <fpage>239</fpage>–<lpage>264</lpage>.</citation></ref>
<ref id="bibr49-0962280211432512"><label>49</label><citation citation-type="other"><comment>Julious SA and Owen RJ. A comparison of methods for sample size estimation for non-inferiority studies with binary outcomes. <italic>Stat Methods Med Res</italic> 2010; DOI: 10.1177/0962280210378945</comment>.</citation></ref>
<ref id="bibr50-0962280211432512"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>JP</given-names></name></person-group>. <article-title>Network meta-analysis of survival data with fractional polynomials</article-title>. <source>BMC Med Res Methodol</source> <year>2011</year>; <volume>11</volume>(<issue>1</issue>): <fpage>61</fpage>–<lpage>61</lpage>.</citation></ref>
<ref id="bibr51-0962280211432512"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Witte</surname><given-names>S</given-names></name><name><surname>Schmidli</surname><given-names>H</given-names></name><name><surname>O’Hagan</surname><given-names>A</given-names></name><name><surname>Racine-Poon</surname><given-names>A</given-names></name></person-group>. <article-title>Designing a non-inferiority study in kidney transplantation: a case study</article-title>. <source>Pharm Stat</source> <year>2011</year>; <volume>10</volume>: <fpage>427</fpage>–<lpage>432</lpage>.</citation></ref>
<ref id="bibr52-0962280211432512"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dias</surname><given-names>S</given-names></name><name><surname>Welton</surname><given-names>NJ</given-names></name><name><surname>Caldwell</surname><given-names>DM</given-names></name><name><surname>Ades</surname><given-names>AE</given-names></name></person-group>. <article-title>Checking consistency in mixed treatment comparison meta-analysis</article-title>. <source>Stat Med</source> <year>2010</year>; <volume>29</volume>(<issue>7–8</issue>): <fpage>932</fpage>–<lpage>944</lpage>.</citation></ref>
<ref id="bibr53-0962280211432512"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gould</surname><given-names>AL</given-names></name></person-group>. <article-title>Another view of active-controlled trials</article-title>. <source>Control Clin Trials</source> <year>1991</year>; <volume>12</volume>(<issue>4</issue>): <fpage>474</fpage>–<lpage>485</lpage>.</citation></ref>
<ref id="bibr54-0962280211432512"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>JG</given-names></name><name><surname>Chen</surname><given-names>MH</given-names></name></person-group>. <article-title>Power prior distributions for regression models</article-title>. <source>Stat Sci</source> <year>2000</year>; <volume>15</volume>: <fpage>46</fpage>–<lpage>60</lpage>.</citation></ref>
<ref id="bibr55-0962280211432512"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neuenschwander</surname><given-names>B</given-names></name><name><surname>Branson</surname><given-names>M</given-names></name><name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name></person-group>. <article-title>A note on the power prior</article-title>. <source>Stat Med</source> <year>2009</year>; <volume>28</volume>(<issue>28</issue>): <fpage>3562</fpage>–<lpage>3566</lpage>.</citation></ref>
<ref id="bibr56-0962280211432512"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hobbs</surname><given-names>BP</given-names></name><name><surname>Carlin</surname><given-names>BP</given-names></name><name><surname>Mandrekar</surname><given-names>SJ</given-names></name><name><surname>Sargent</surname><given-names>DJ</given-names></name></person-group>. <article-title>Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials</article-title>. <source>Biometrics</source> <year>2011</year>; <volume>67</volume>(<issue>3</issue>): <fpage>1047</fpage>–<lpage>1056</lpage>.</citation></ref>
<ref id="bibr57-0962280211432512"><label>57</label><citation citation-type="other"><comment>CHMP. <italic>Points to consider in application with 1. Meta-analysis; 2. One pivotal study</italic>. London: The European Agency for the Evaluation of Medicinal Products, CPMP/EWP/2330/99, <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003657.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003657.pdf</ext-link> (2001, accessed January 2011)</comment>.</citation></ref>
<ref id="bibr58-0962280211432512"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Julious</surname><given-names>SA</given-names></name><name><surname>Wang</surname><given-names>SJ</given-names></name></person-group>. <article-title>Issues with indirect comparisons in clinical trials particularly with respect to non-inferiority trials</article-title>. <source>Drug Inf J</source> <year>2008</year>; <volume>42</volume>(<issue>6</issue>): <fpage>625</fpage>–<lpage>633</lpage>.</citation></ref>
<ref id="bibr59-0962280211432512"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name><name><surname>Best</surname><given-names>NG</given-names></name><name><surname>Carlin</surname><given-names>BP</given-names></name><name><surname>Van Der Linde</surname><given-names>A</given-names></name></person-group>. <article-title>Bayesian measures of model complexity and fit</article-title>. <source>J Royal Stat Soc Ser B</source> <year>2002</year>; <volume>64</volume>: <fpage>583</fpage>–<lpage>639</lpage>.</citation></ref>
<ref id="bibr60-0962280211432512"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Julious</surname><given-names>SA</given-names></name></person-group>. <article-title>Time to end the non-inferiority complex?</article-title> <source>Pharm Stat</source> <year>2011</year>; <volume>10</volume>: <fpage>393</fpage>–<lpage>394</lpage>.</citation></ref>
<ref id="bibr61-0962280211432512"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alderson</surname><given-names>NE</given-names></name><name><surname>Campbell</surname><given-names>G</given-names></name><name><surname>D’Agostino</surname><given-names>R</given-names></name><name><surname>Ellenberg</surname><given-names>S</given-names></name><name><surname>Lindborg</surname><given-names>S</given-names></name><name><surname>O’Neill</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Statistical issues: a roundtable discussion</article-title>. <source>Clin Trials</source> <year>2005</year>; <volume>2</volume>: <fpage>364</fpage>–<lpage>372</lpage>.</citation></ref>
</ref-list>
<app-group><app id="app1-0962280211432512"><title/>
<sec id="sec22-0962280211432512"><title>Appendix</title><p>WinBUGS code for the basic network meta-analysis model for three treatments, combining the non-inferiority trial and K historical trials. The non-inferiority trial compares test treatment (T) with the active-control (C). The historical trials compare the active-control (C) with placebo (P). For the examples of Section 3, the burn-in, number of saved iterations and number of chains were 5000, 50 000 and 3 (total number of iterations = simulations saved = 150 000).</p>
<p># Historical studies are index 1:K, NI study has index K + 1</p>
<p># Treatment indices are 1 (active-control), 2 (placebo), 3 (test)</p>
<p>model{</p>
<p># sampling distribution</p>
<p>for (j in 1:Nobs) {</p>
<p> r[j] ∼ dbin(p[study[j],trt[j]],n[j])</p>
<p>}</p>
<p># model parameters by study</p>
<p>for (i in 1:Nstudies) {</p>
<p> # logit of pC</p>
<p> theta[i] ∼ dnorm(mu.theta,prec.tau.theta)</p>
<p> # logOR(P vs. C), logOR(T vs. C) from bivariate normal</p>
<p> delta[i,1:2] ∼ dmnorm(mu.delta[1:2],prec.tau.delta[1:2,1:2])</p>
<p> # parameters for C, P, and T</p>
<p> logit.p[i,1]&lt;- theta[i]</p>
<p> logit.p[i,2]&lt;- theta[i] + delta[i,1]</p>
<p> logit.p[i,3] &lt;- theta[i] + delta[i,2]</p>
<p> p[i,1] &lt;- 1/(1+exp(-logit.p[i,1]))</p>
<p> p[i,2] &lt;- 1/(1+exp(-logit.p[i,2]))</p>
<p> p[i,3] &lt;- 1/(1+exp(-logit.p[i,3]))</p>
<p>}</p>
<p># main parameters of interest (for NI study)</p>
<p>NI.logOR[2,1] &lt;- delta[Nstudies,1]</p>
<p>NI.logOR[3,1] &lt;- delta[Nstudies,2]</p>
<p>NI.logOR[3,2] &lt;- delta[Nstudies,2]-delta[Nstudies,1]</p>
<p>NI.OR[2,1] &lt;- exp(NI.logOR[2,1])</p>
<p>NI.OR[3,1] &lt;- exp(NI.logOR[3,1])</p>
<p>NI.OR[3,2] &lt;- exp(NI.logOR[3,2])</p>
<p>NI.OR[1,2] &lt;- 1/NI.OR[2,1]</p>
<p>NI.OR[1,3] &lt;- 1/NI.OR[3,1]</p>
<p>NI.OR[2,3] &lt;- 1/NI.OR[3,2]</p>
<p>NI.greater[2,1] &lt;- step(NI.OR[2,1]-1)</p>
<p>NI.greater[3,1] &lt;- step(NI.OR[3,1]-1)</p>
<p>NI.greater[3,2] &lt;- step(NI.OR[3,2]-1)</p>
<p># Priors</p>
<p># prior for mean of random-effects logit(p_Ci) = theta_Ci</p>
<p>mu.theta ∼ dnorm(prior.mu.theta.mean,mu.prior.prec)</p>
<p>mu.prior.prec &lt;- pow(prior.mu.theta.sd,-2)</p>
<p># mean of bivariate random-effects delta[1:2]</p>
<p># logOR (P vs C), logOR(T vs C)</p>
<p>mu.delta[1:2] ∼ dmnorm(prior.mu.delta.mean[1:2],prior.mu.delta.prec[1:2,1:2])</p>
<p>prior.mu.delta.prec[1:2,1:2] &lt;- inverse(prior.mu.delta.cov[1:2,1:2])</p>
<p>mu.delta[3] &lt;- mu.delta[2]-mu.delta[1]</p>
<p># half-normal prior for tau.theta = sd of logit(pCi)</p>
<p>tau.theta ∼ dnorm(0,prior.tau.theta.prec)I(0,)</p>
<p>prior.tau.theta.prec &lt;- pow(prior.tau.theta.sd,-2)</p>
<p>prec.tau.theta &lt;- pow(tau.theta,-2)</p>
<p># half-normal prior for tau.delta = sd of logOR(P vs C) and logOR(T vs C)</p>
<p>tau.delta ∼ dnorm(0,prior.tau.delta.prec)I(0,)</p>
<p>prior.tau.delta.prec &lt;- pow(prior.tau.delta.sd,-2)</p>
<p># covariance matrix of random-effects distribution for deltas</p>
<p>cov.delta[1,1] &lt;- pow(tau.delta,2)</p>
<p>cov.delta[1,2] &lt;- pow(tau.delta,2)*rho.delta</p>
<p>cov.delta[2,1] &lt;- pow(tau.delta,2)*rho.delta</p>
<p>cov.delta[2,2] &lt;- pow(tau.delta,2)</p>
<p>prec.tau.delta[1:2,1:2] &lt;- inverse(cov.delta[1:2,1:2])</p>
<p>}</p>
<p># data and priors</p>
<p>list(Nstudies = 7, Nobs = 14,</p>
<p>study = c(1, 1, 2, 2, 3, 3, 4, 4, 5, 5, 6, 6, 7, 7),</p>
<p>trt = c(1, 2, 1, 2, 1, 2, 1, 2, 1, 2, 1, 2, 1, 3),</p>
<p>r = c(2, 4, 3, 7, 0, 1, 4, 9, 42, 40, 4, 7, 121, 99),</p>
<p>n = c(122,121,210,189,37,32,105,109,154,131,70,73,1564,1607),</p>
<p># weakly informative priors for mean of random-effects distributions</p>
<p># mean of theta_C = logit(pC) parameters</p>
<p>prior.mu.theta.mean = 0, prior.mu.theta.sd = 100,</p>
<p># mean of delta[1:2] (log-odds-ratios P vs C and T vs C</p>
<p>prior.mu.delta.mean = c(0,0),</p>
<p>prior.mu.delta.cov = structure(.Data = c(10000,0,0,10000),.Dim = c(2,2)),</p>
<p># sd of halfnormal distribution for random-effects standard deviations</p>
<p>prior.tau.theta.sd = 0.5, prior.tau.delta.sd = 0.25,</p>
<p># correlation for deltas</p>
<p>rho.delta = 0.5)</p>
<p># initial values</p>
<p>list(mu.theta = −2, mu.delta = c(0,0,NA), tau.theta = 0.1, tau.delta = 0.1)</p>
</sec></app></app-group></back>
</article>